



(86) Date de dépôt PCT/PCT Filing Date: 2013/09/27

(87) Date publication PCT/PCT Publication Date: 2014/04/10

(45) Date de délivrance/Issue Date: 2021/01/26

(85) Entrée phase nationale/National Entry: 2015/03/31

(86) N° demande PCT/PCT Application No.: US 2013/062410

(87) N° publication PCT/PCT Publication No.: 2014/055370

(30) Priorité/Priority: 2012/10/01 (US61/708,554)

(51) Cl.Int./Int.Cl. *C12N 5/07* (2010.01),
C07K 16/00 (2006.01)


(72) Inventeurs/Inventors:
VARMA, AMIT, US;
CUENCA, JAMES, US;
ZHU, YING, US

(73) Propriétaire/Owner:
ABBVIE BIOTHERAPEUTICS INC., US

(74) Agent: TORYS LLP

(54) Titre : COMPOSITIONS ET PROCEDES DE PRODUCTION DE GLYCOPROTEINES

(54) Title: COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS



(57) Abrégé/Abstract:

The present disclosure relates to methods of producing antibodies with increased levels of non-fucosylated glycoforms by culturing mammalian cells in culture media with enhanced concentrations of glycine relative to traditional basal media.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

10 April 2014 (10.04.2014)



(10) International Publication Number

WO 2014/055370 A1

(51) International Patent Classification:

C12N 5/07 (2010.01) C07K 16/00 (2006.01)

(21) International Application Number:

PCT/US2013/062410

(22) International Filing Date:

27 September 2013 (27.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/708,554 1 October 2012 (01.10.2012) US

(71) Applicant: ABBVIE BIOTHERAPEUTICS INC. [US/US]; 1500 Seaport Boulevard, Redwood City, California 94063 (US).

(72) Inventors: VARMA, Amit; 35140 King Court, Fremont, California 94536 (US). CUENCA, James; 1029 Emerald Terrace, Union City, California 94587 (US). ZHU, Ying; 865 Forest Ave., Palo Alto, California 94301 (US).

(74) Agents: SNYDER, Seth E. et al.; Dechert LLP, 2440 W. El Camino Real, Suite 700, Mountain View, California 94040-1499 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS




FIGURE 5

(57) Abstract: The present disclosure relates to methods of producing antibodies with increased levels of non-fucosylated glycoforms by culturing mammalian cells in culture media with enhanced concentrations of glycine relative to traditional basal media.

COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS

1. SEQUENCE LISTING

[0001]

2. BACKGROUND

[0002] Post-translational modification of proteins through glycosylation leads to the formation of distinct glycoforms, which often have unique properties. Differences in glycosylation of proteins can have a profound influence on the physical and chemical properties of the protein, including the binding affinity of the protein to a particular target molecule. Several methods of modulating glycosylation of proteins are known. Different expression systems can impart distinct glycosylation profiles. Moreover, protein coding sequences can be modified to produce proteins with an enhanced or decreased level of a particular glycoform. The conditions under which recombinant cell lines are cultured can also influence the glycosylation profile.

[0003] Antibodies produced recombinantly in mammalian cells are often glycosylated at both the Fc and the Fab regions of the antibody. Many glycosylated antibodies contain the sugar fucose. The presence of fucose in an antibody can influence the binding of the antibody to particular proteins on cells. For instance, antibodies containing high levels of fucose in the Fc region of the antibody can have diminished binding to receptors on lymphocytes (*e.g.*, natural killer cells). Antibodies lacking fucose have been correlated with enhanced ADCC (antibody-dependent cellular cytotoxicity) activity, especially at low doses of antibody. Shields *et al.*, 2002, J. Biol. Chem. 277:26733-26740; Shinkawa *et al.*, 2003, J. Biol. Chem. 278:3466. Methods of preparing fucose-less antibodies include growth in rat myeloma YB2/0 cells (ATCC CRL 1662). YB2/0 cells express low levels of FUT8 mRNA, which encodes an enzyme (α 1,6-fucosyltransferase) necessary for fucosylation of proteins. Alternative methods for increasing ADCC activity include mutations in the Fc portion of an antibody, particularly mutations which increase antibody affinity for an Fc γ R receptor. A correlation between increased Fc γ R binding with mutated Fc has been demonstrated using targeted cytotoxicity cell-based assays. Shields *et al.*, 2001, J. Biol. Chem. 276:6591-6604; Presta *et al.*, 2002, Biochem Soc. Trans. 30:487-490.

[0004] The concentration of components in a culture medium or feed medium may influence the glycosylation profile of a protein. Ideally, a particular glycoform of a protein may be enhanced or diminished through control of the conditions under which recombinant cell lines are grown. While there

have been a multitude of studies directed to increasing the yields of proteins through manipulating the components of a culture medium, there have been far fewer reports concerned with modulating glycosylation of proteins through modifying the cell culture medium in which recombinantly engineered cells are cultured. One example is disclosed in U.S. Patent No. 5,705,364, which is directed to a process for controlling the content of sialic acid of glycoproteins produced by mammalian cells through the addition of an alkanoic acid to the culture medium. However, the possibility of increasing ADCC activity of antibodies through modifications of the culture media in which recombinant antibodies are expressed has not been sufficiently addressed. Accordingly, developing a cell culture medium for culturing mammalian cells to express antibodies with reduced levels of fucose and increased ADCC activity would be highly desirable.

3. SUMMARY OF THE DISCLOSURE

[0005] The present disclosure relates to the discovery that glycoproteins (*e.g.*, antibodies) with beneficial properties are produced by culturing mammalian cells in a culture medium comprising a high concentration (*e.g.*, at least 5 mM) of glycine, (hereinafter “high glycine medium”). In particular, culturing mammalian host cells in high glycine media increases levels of non-fucosylated glycoforms. The mammalian cells can be used to produce antibodies that display enhanced biological activity, including enhanced antibody dependent cellular cytotoxicity (“ADCC”) activity.

[0006] Accordingly, the disclosure generally provides methods and compositions for expressing recombinant proteins (*e.g.*, antibodies) with modified glycosylation profiles as compared to glycoproteins expressed in traditional culture media. The methods and compositions utilize high glycine media to express glycoproteins, such as antibodies, in mammalian cells, advantageously result in glycoproteins with reduced fucosylation levels as compared to glycoproteins produced in traditional culture media.

[0007] Additionally, the methods of the disclosure can be used to modulate and control protein glycosylation during manufacturing. Improved control of product glycosylation during manufacturing is desirable since it will reduce the risk of batch rejection and improve control during technology transfer between manufacturing sites and during scale-up of the process. Therefore, the methods can be used to maintain reproducible product glycosylation profiles without introducing process changes.

[0008] Mammalian cells capable of being engineered to produce recombinant glycoproteins include NS0 cells, CHO cells, mouse myeloma SP2/0 cells, baby hamster kidney BHK-21 cells and human embryonic kidney HEK0291 cells. In particular embodiments, NS0 cells are recombinantly engineered to produce antibodies.

[0009] In one aspect, the disclosure provides culture media suitable for mammalian cell culture comprising glycine at a concentration between 5 mM and 100 mM and optionally other amino acids at various concentrations as indicated in the disclosure. The culture medium is preferably a chemically-defined, protein free medium. The concentration of glycine in the cell culture medium can be, for instance, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 22 mM, 25 mM, 30 mM or 50 mM. In certain embodiments, the concentration of glycine in the cell culture medium is bounded by any of the two foregoing embodiments, *e.g.*, a concentration ranging from 5 mM to 10 mM, from 7 mM to 10 mM, from 10 mM to 15 mM, from 12 mM to 17 mM, from 15 mM to 20 mM, from 16 mM to 18 mM from 10 mM to 30 mM, from 10 mM to 25 mM, from 20 mM to 30 mM, from 10 mM to 50 mM, from 20 mM to 50 mM, *etc.* Other amino acids can be present in the culture medium, generally at concentrations typically found in a traditional basal medium. In one embodiment, concentrations of the amino acids in the culture media of the present disclosure are found in ranges listed in Table 2. The culture medium can also include one or more additional components such as vitamins, trace elements, energy sources, fatty acids, growth factors, nucleosides, lipids, hormones and/or antibiotics. Furthermore, the medium can include a buffer, an osmolality regulator and/or a surfactant. Further details of such additional components can be found in Section 5.1.

[0010] In another aspect, one or more amino acids other than glycine have concentrations at or below the concentrations shown in Table 3 or Table 4. For instance, two, three, four, five, six, seven, eight, nine, ten or eleven amino acids can have concentrations at or below the concentrations listed in Table 3 or Table 4. In one embodiment, the concentration of lysine in the culture medium is between 0.5 mM and 5.0 mM.

[0011] In another aspect, the present disclosure provides methods for producing a glycoprotein of interest (“GOI”), *e.g.* an antibody of interest (“AOI”), comprising culturing mammalian cells, *e.g.* NS0 cells, engineered to secrete and express the GOI or AOI in a cell culture medium comprising glycine at a concentration of at least 5 mM, for example 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 22 mM, 25 mM or 30 mM. The AOI can be, for instance, a murine antibody, a humanized antibody, a chimeric antibody or a fully human antibody. In specific embodiments, the concentration of glycine in the cell culture medium is bounded by any of the two foregoing embodiments, *e.g.*, a concentration of glycine ranging from 5 mM to 10 mM, from 7 mM to 10 mM, from 10 mM to 15 mM, from 12 mM to 17 mM, from 15 mM to 20 mM, from 16 mM to 18 mM, from 10 mM to 30 mM, from 10 mM to 25 mM, from 20 mM to 30 mM, *etc.* In certain embodiments, the culture medium is a chemically defined protein free medium.

[0012] In one embodiment, the AOI is HuLuc63 (elotuzumab). The amino acid sequence of the mature V_H chain of elotuzumab (SEQ ID NO:1), the mature V_L chain of elotuzumab (SEQ ID NO:2), the full heavy chain sequence of elotuzumab (SEQ ID NO:3) and the full light chain sequence of elotuzumab (SEQ ID NO:4) are shown in Table 7. The cell culturing processes of the present disclosure produce a population of elotuzumab molecules in which at least 4% of the glycans lack fucose and in which at least 2.5% of the glycans are Mannose5 glycans. In one embodiment, the cell culturing processes of the present disclosure produce a population of elotuzumab molecules in which at least 5% of the glycans lack fucose and in which at least 3% of the glycans are Mannose5 glycans.

[0013] In another embodiment, the antibody of interest is daclizumab. The amino acid sequence of the mature V_H chain of daclizumab (SEQ ID NO:5), the mature V_L chain of daclizumab (SEQ ID NO:6), the full heavy chain sequence of daclizumab (SEQ ID NO:7) and the full light chain sequence of daclizumab (SEQ ID NO:8) are shown in Table 7. The cell culturing process of the present disclosure produces a population of daclizumab molecules in which at least 3% of the glycans lack fucose and in which at least 1.5% of the glycans are Mannose5 glycoforms. In one embodiment, the cell culturing process of the present disclosure produces a population of daclizumab molecules in which at least 4% of the glycans lack fucose and in which at least 2% of the glycans are Mannose5 glycans.

[0014] In another embodiment, the AOI is voloxitimab. The amino acid sequence of the mature V_H chain of voloxitimab (SEQ ID NO:9), the mature V_L chain of voloxitimab (SEQ ID NO:10), the full heavy chain sequence of voloxitimab (SEQ ID NO:11) and the full light chain sequence of voloxitimab (SEQ ID NO:12) are shown in Table 7. The cell culturing processes of the present disclosure produce a population of voloxitimab molecules in which at least 1% of the molecules lack fucose and in which at least 0.5% of the glycans are Mannose5 glycans.

[0015] In a further embodiment, the AOI is PDL241. The amino acid sequence of the mature V_H chain of PDL241 (SEQ ID NO:13), the mature V_L chain of PDL241 (SEQ ID NO:14), the full heavy chain sequence of PDL241 (SEQ ID NO:15), the full light chain sequence of PDL241 (SEQ ID NO:16) are shown in Table 7. The cell culturing processes of the present disclosure produce a population of PDL241 molecules in which at least 14% of the glycans lack fucose and in which at least 8% of the glycans are Mannose5 glycans. In one embodiment, the cell culturing processes of the present disclosure produce a population of PDL241 molecules in which at least 15% of the glycans lack fucose and in which at least 9% of the glycans are Mannose5 glycans.

[0016] In yet another embodiment, the AOI is PDL192 (enavatuzumab). The amino acid sequence of the mature V_H chain of enavatuzumab (SEQ ID NO:17), the mature V_L chain of enavatuzumab (SEQ ID NO:18), the full heavy chain sequence of enavatuzumab (SEQ ID NO:19) and the full light chain

sequence of enavatuzumab (SEQ ID NO:20) are shown in Table 7. The cell culturing processes of the present disclosure produce a population of enavatuzumab molecules in which at least 5% of the glycans lack fucose and in which at least 2.5% of the glycans are Mannose5 glycans. In one embodiment, the cell culturing processes of the present disclosure produce a population of enavatuzumab molecules in which at least 6% of the glycans lack fucose and in which at least 3% of the glycans are Mannose5 glycans.

4. BRIEF DESCRIPTION OF FIGURES

[0017] FIGURE 1 shows the structure of some typical N-linked glycans.

[0018] FIGURE 2 shows the relative amount of non-fucosylated G0 glycans without GlcNAc (N-acetylglucosamine) attached in five different antibodies produced by NS0 cells cultured in basal medium supplemented with additional glycine. The amount is expressed as a percentage relative to the amount of the glycans present in antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

[0019] FIGURE 3 shows the relative amount of Mannose5 (Man5) glycans attached in five different antibodies produced by NS0 cells cultured in basal medium with a glycine concentration of 17mM. The amount is expressed as a percentage relative to the amount of the glycans present in antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

[0020] FIGURE 4 shows the relative amount of total non-fucosylated glycans attached in five different antibodies produced by NS0 cells cultured in basal medium s with a glycine concentration of 17 mM. The amount is expressed as a percentage relative to the amount of the glycans present in antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

[0021] FIGURE 5 shows the relative amounts of non-fucosylated G0 glycoform without GlcNAc (N-acetylglucosamine) and Man5-type glycoforms attached in PDL192 produced by NS0 cells cultured in basal medium supplemented with different concentrations of glycine (5, 15, 30 mM). The amount is expressed as a percentage relative to the amount of the glycoform present in antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

[0022] FIGURE 6 shows the relative binding potency to the CD16a receptor for four IgG1 antibodies (clotuzumab, daclizumab, PDL192 and PDL241) produced by NS0 cells cultured in basal medium supplemented with additional glycine. The amount is expressed as a percentage relative to the CD16a binding affinities of the same antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

[0023] FIGURE 7 shows the relative binding potency to the CD16a receptor for PDL192 (enavatuzumab) produced by NS0 cells cultured in basal medium supplemented with different

concentrations of glycine (5, 15, 30 mM). The amount is expressed as a percentage relative to the CD16a binding affinities of the same antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

[0024] FIGURES 8A-C show the ADCC activity of elotuzumab produced from both the control and high glycine process. The studies were performed on human peripheral blood mononuclear cells (PBMCs) from three different donors. Negative controls were included in the assays using a control antibody without ADCC activity and samples without antibody addition.

[0025] FIGURES 9A-B show the ADCC activity of PDL 241 produced from both the control and high glycine process. The studies were performed on PBMC from two different donors. Negative controls were included in the assays using a control antibody without ADCC activity and samples without antibody addition.

[0026] FIGURES 10A-B show the ADCC activity of PDL192 (enavatuzumab) produced from both the control and high glycine process. The studies were performed on PBMC from two different donors. Negative controls were included in the assays using a control antibody without ADCC activity and samples without antibody addition.

[0027] FIGURES 11A-B show the ADCC activity of daclizumab produced from both the control and high glycine process. The studies were performed on PBMC from two different donors. Negative controls were included in the assays using a control antibody without ADCC activity and samples without antibody addition.

5. DETAILED DESCRIPTION OF THE DISCLOSURE

[0028] The present disclosure relates to compositions and methods for recombinant glycoprotein (*e.g.*, antibody) expression. The compositions and methods produce glycoproteins with reduced fucosylated glycoforms and increased ADCC activity as compared to glycoprotein produced in traditional culture media. Antibodies produced by expression systems utilizing the compositions and methods of the disclosure advantageously display less fucosylation than when produced by culturing in traditional media. Various aspects of the disclosure are described below. Section 5.1 describes culture media containing elevated concentrations (*i.e.*, high glycine media) that are suitable for culturing mammalian cells capable of expressing proteins. Section 5.2 describes various glycoproteins (*e.g.*, antibodies) that can be produced in high glycine media. Section 5.3 describes nucleic acids and expression systems for producing glycoproteins. Section 5.4 describes culture methods that can be used to produce glycoproteins. Section 5.5 describes methods of recovering and purifying glycoproteins produced by methods of the disclosure. Section 5.6 describes glycoprotein populations produced by methods of the disclosure. Section 5.7

describes pharmaceutical compositions of glycoproteins produced by methods of the disclosure. Section 5.8 describes methods of treating various diseases using exemplary antibodies produced by methods of the present disclosure.

5.1. Cell Culture Media

[0029] In one aspect, the present disclosure provides a culture medium suitable for mammalian cell culture comprising high concentrations of glycine. As used herein, the term “culture medium” refers to a medium suitable for growth of mammalian cells in an *in vitro* cell culture. As used herein, the term “cell culture” or “culture” refers to the growth of mammalian cells in an *in vitro* environment. A typical culture medium contains amino acids, vitamins, trace elements, free fatty acids, and an energy source. Additional growth components such as growth factors, nucleosides, lipids, hormones and antibiotics can be included in the culture medium. Furthermore, the medium can include a buffer, an osmolality regulator and a surfactant.

[0030] As will be recognized by skilled artisan, the culture and feed media used to culture cells for recombinant protein (*e.g.*, antibody) production, as well as other variables such as the feeding schedule, growth rate, temperature, and oxygen levels, can affect the yield and quality of the expressed protein. Methods of optimizing these conditions are within the purview of a skilled artisan; exemplary conditions are set forth in the Exemplary Embodiments of the disclosure. Preferably, cells are adapted to grow in media free of cholesterol-, serum-, and other animal-sourced components; in such instances the culture and feed media preferably include defined chemicals that substitute for such components. Accordingly, the methods of producing recombinant proteins can comprise culturing a recombinant mammalian cell of the present disclosure in a chemically defined medium, free of animal-derived components.

[0031] The culture media of the disclosure are high glycine media. As used herein, the term “high glycine medium” refers to a medium in which the concentration of glycine is higher than the concentration of glycine found in typical cell culture media. As shown in Table 1 below, concentrations of glycine in commercial culture media (*e.g.*, basal media) range from about 0.1 mM to about 2 mM.

TABLE 1	
Medium	Glycine Concentration (mM)
DMEM	0.4
DMEM/F12	0.25
IMDM	0.4
MEM, Ham's F12	0.1
Medium 199	0.67
Medium supplemented with hydrolysate at 5 g/L (assuming 3% glycine)	2.0

Table 1: Concentration of glycine in typical commercial culture media

[0032] The concentration of glycine in the culture media of the disclosure are preferably 5 mM or greater. For instance, the concentration of glycine in the culture media can be from 5 mM to 100 mM (*e.g.*, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 22 mM, 25 mM, 30 mM or 50 mM). In specific embodiments, the concentration of glycine in the culture medium can be bounded by any of the two foregoing values, such as, but not limited to, a concentration ranging from 5 mM to 10 mM, from 7 mM to 10 mM, from 10 mM to 15 mM, from 12 mM to 17 mM, from 15 mM to 20 mM, from 16 mM to 18 mM, from 10 mM to 30 mM, from 10 mM to 25 mM, from 20 mM to 30 mM, from 10 mM to 50 mM or from 20 mM to 50 mM.

[0033] The culture media of the present disclosure can contain a variety of amino acids in addition to glycine. For instance, the culture media can contain other amino acids including alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. In particular embodiments, the culture media can contain amino acids (other than glycine) present in concentrations that they are normally found in traditional media (*e.g.*, basal media). Suitable amino acids have concentrations in the ranges listed in Table 2.

TABLE 2	
Amino Acid	Concentration of Amino Acid in the Medium (mM)
Alanine	0.01-0.07
Arginine	0.6-1.6
Asparagine	0.08-1.5
Aspartic Acid	0.03-0.4
Cysteine	0.1-0.9
Glutamic Acid	0.03-0.1
Glutamine	2-12
Glycine	8-35
Histidine	0.09-0.7
Isoleucine	0.9-1.7
Leucine	1-1.8
Lysine	0.8-1.6
Methionine	0.1-0.5
Phenylalanine	0.2-1
Proline	0.5-4
Serine	0.1-0.8
Threonine	0.7-1.5
Tryptophan	0.08-0.3
Tyrosine	0.2-3
Valine	0.8-1.6

Table 2: Exemplary concentration ranges of amino acids in the culture media of the present disclosure

[0034] In certain embodiments, the disclosure provides a culture medium in which glycine is at a concentration from 5 mM to 30 mM, and in which one or more amino acids other than glycine have concentrations at or below the concentrations listed in Table 3. For instance, two, three, four, five, six, seven, eight, nine, ten or eleven amino acids can have concentrations at or below the concentrations at or below the concentrations listed in Table 3. In one embodiment, the concentration of lysine in the culture medium is between 0.5 mM and 5.0 mM. Other amino acids not identified in Table 2 can be present in the culture medium, for instance, at concentrations in the ranges listed in Table 2.

TABLE 3		
Amino Acid	Concentration of Amino Acid in Medium (mM)	Concentration of Amino Acid in Medium (mg/L)
Asparagine	2 mM	264
Aspartic Acid	2 mM	266
Isoleucine	2 mM	262
Leucine	2.5 mM	328
Lysine	6 mM	876
Methionine	0.45 mM	67
Serine	4 mM	420
Threonine	4 mM	476
Tryptophan	0.3 mM	61
Tyrosine	2.5 mM	145
Valine	1.8 mM	211

Table 3: Exemplary maximum concentrations of particular amino acids in culture media of certain embodiments of the present disclosure

[0035] In other aspects, the disclosure provides a culture medium in which glycine is at a concentration from 5 mM to 30 mM, and in which one or more amino acids other than glycine have concentrations at or below the concentrations listed in Table 4. For instance, two, three, four, five, six, seven, eight, nine, ten or eleven amino acids can have concentrations at or below the concentrations at or below the concentrations listed in Table 4. Other amino acids not identified in Table 3 can be present in the culture medium, for instance, at concentrations in the ranges listed in Table 2.

TABLE 4		
Amino Acid	Concentration of Amino Acid in Medium (mM)	Concentration of Amino Acid in Medium (mg/L)
Asparagine	1.5 mM	198
Aspartic Acid	1.5 mM	200
Isoleucine	1.5 mM	197
Leucine	2 mM	262
Lysine	4 mM	584
Methionine	0.4 mM	60
Serine	2 mM	210
Threonine	2 mM	238
Tryptophan	0.2 mM	41

TABLE 4		
Amino Acid	Concentration of Amino Acid in Medium (mM)	Concentration of Amino Acid in Medium (mg/L)
Tyrosine	1.5 mM	128
Valine	1.5 mM	178

Table 4: Exemplary maximum concentrations of particular amino acids in the culture media of certain embodiments of the present disclosure

[0036] Additionally, the culture media of the present disclosure can contain a variety of vitamins. Typical vitamins include, but are not limited to, vitamin B-12, biotin, choline, folic acid, nicotinamide, calcium pantothenate, pyridoxal hydrochloride, riboflavin and thiamine hydrochloride. The vitamins can suitably be used in the concentration ranges shown in Table 5.

TABLE 5	
Vitamin	Concentration of Vitamin in the Medium (mM)
Vitamin B-12	0.00013-0.002
Biotin	0.00001- 0.01
Choline	0.016-1.3
Folic Acid	0.0015-0.02
Niacinamide	0.002-0.07
Calcium pantothenate	0.012-0.02
Pyridoxal hydrochloride	0-0.04
Riboflavin	0.00015-0.0023
Thiamine hydrochloride	0-0.3

Table 5: Exemplary concentrations of vitamins in the culture media of the present disclosure

[0037] Additionally, the cell culture media of the present disclosure can contain a variety of trace elements. Typical trace elements include, but are not limited to, calcium chloride anhydrous, magnesium chloride anhydrous, magnesium sulfate anhydrous, potassium chloride and sodium phosphate dibasic anhydrous. The trace elements can suitably be used in the culture media in concentration ranges shown in Table 6.

TABLE 6	
Trace Element	Concentration of Trace Element in the Medium (mM)
Calcium chloride anhydrous	0.2-1.1
Magnesium chloride anhydrous	0.1-1.
Magnesium sulfate anhydrous	0.1-1.1
Potassium Chloride	2-8
Sodium phosphate dibasic anhydrous	0.5-5

Table 6: Exemplary concentrations of trace elements in culture media of the present disclosure

[0038] The culture media can also include at least one energy source. Examples of energy sources that may be included in the cell culture include glucose, mannose, galactose, maltose and fructose. Glucose can be added to the culture medium at a concentration ranging from 5 g/L to 20 g/L.

[0039] The culture media of the present disclosure can also contain a buffer. A buffer is used to maintain the cell culture at a suitable pH. Buffers that can be used in the culture medium include but are not limited to HEPES, phosphate buffer (*e.g.*, mono- and di-basic sodium phosphate) and sodium carbonate. The buffer can be used to maintain the pH of the culture medium in an acceptable range, typically at a pH ranging from 6.5 to 7.5 and more typically at a pH ranging from 6.8 to 7.2.

[0040] The culture media can contain salts to regulate osmolality. For instance, an osmolality regulator is typically added to maintain the osmolality of the culture medium in a range between 250-400 milli-Osmols (mOsm), and more typically between 270-350 mOsm. Characteristic osmolality regulators include salts such as sodium chloride or potassium chloride. It will be appreciated by one of skill in the art that high glycine amounts in a culture medium will affect the osmolality of the medium. Accordingly, the osmolality of the culture medium can be maintained in an appropriate range by reducing the amount of osmolality regulator added to the medium after accounting for the osmolality contributed by the high glycine levels.

[0041] The culture media of the present disclosure can also contain a lipid factor. Typical lipid factors, include, but are not limited to lipoic acid, choline chloride, oleic acid, and phosphatidylcholine.

5.2. Glycoproteins

[0042] The present disclosure provides glycoproteins enriched in non-fucosylated glycoforms. Section 5.2.1 describes antibodies that can be produced by methods of the present disclosure. Section 5.2.2 describes other types of glycoproteins than can be produced by methods of the disclosure.

5.2.1. Antibodies

[0043] Antibodies (Abs) and immunoglobulins (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific target, immunoglobulins include both antibodies and other antibody-like molecules which lack target specificity. Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end.

[0044] The present disclosure provides antibodies enriched in non-fucosylated glycoforms. Unless indicated otherwise, the term “antibody” (Ab) refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with, a particular antigen, and includes polyclonal, monoclonal, genetically engineered and otherwise modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (*e.g.*, bispecific antibodies, diabodies, triabodies, and tetrabodies), and antigen binding fragments of antibodies, including *e.g.*, Fab', F(ab')₂, Fab, Fv, rIgG, and scFv fragments. Moreover, unless otherwise indicated, the term “monoclonal antibody” (mAb) is meant to include both intact molecules, as well as, antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to a protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation of the animal, and may have less non-specific tissue binding than an intact antibody (Wahl *et al.*, 1983, J. Nucl. Med. 24:316). The term “scFv” refers to a single chain Fv antibody in which the variable domains of the heavy chain and the light chain from a traditional antibody have been joined to form one chain.

[0045] References to “VH” refer to the variable region of an immunoglobulin heavy chain of an antibody, including the heavy chain of an Fv, scFv, or Fab. References to “VL” refer to the variable region of an immunoglobulin light chain, including the light chain of an Fv, scFv, dsFv or Fab.

[0046] Both the light chain and the heavy chain variable domains have complementarity determining regions (CDRs), also known as hypervariable regions. The more highly conserved portions of variable domains are called the framework (FR). As is known in the art, the amino acid position/boundary delineating a hypervariable region of an antibody can vary, depending on the context and the various

definitions known in the art. Some positions within a variable domain may be viewed as hybrid hypervariable positions in that these positions can be deemed to be within a hypervariable region under one set of criteria while being deemed to be outside a hypervariable region under a different set of criteria. One or more of these positions can also be found in extended hypervariable regions. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the target binding site of antibodies (see Kabat *et al.*, Sequences of Proteins of Immunological Interest (National Institute of Health, Bethesda, Md. 1987). As used herein, numbering of immunoglobulin amino acid residues is done according to the immunoglobulin amino acid residue numbering system of Kabat *et al.*, unless otherwise indicated.

[0047] Antibody fragments can also be produced utilizing the compositions and methods of the disclosure. The term “antibody fragment” refers to a portion of a full-length antibody, generally the target binding or variable region. Examples of antibody fragments include Fab, Fab', F(ab')₂ and Fv fragments. An “Fv” fragment is the minimum antibody fragment which contains a complete target recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (VH -VL dimer). It is in this configuration that the three CDRs of each variable domain interact to define a target binding site on the surface of the VH -VL dimer. Often, the six CDRs confer target binding specificity to the antibody. However, in some instances even a single variable domain (or half of an Fv comprising only three CDRs specific for a target) can have the ability to recognize and bind target. “Single-chain Fv” or “scFv” antibody fragments comprise the VH and VL domains of an antibody in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for target binding. “Single domain antibodies” are composed of a single VH or VL domains which exhibit sufficient affinity to the target. In a specific embodiment, the single domain antibody is a camelized antibody (see, *e.g.*, Riechmann, 1999, Journal of Immunological Methods 231:25–38).

[0048] The Fab fragment contains the constant domain of the light chain and the first constant domain (CH₁) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH₁ domain including one or more cysteines from the antibody hinge region. F(ab') fragments are produced by cleavage of the disulfide bond at the hinge cysteines of the F(ab')₂ pepsin digestion product. Additional chemical couplings of antibody fragments are known to those of ordinary skill in the art.

[0049] In certain embodiments, the antibodies of the disclosure are monoclonal antibodies. The term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology. The term “monoclonal antibody” refers to an antibody that is derived from a single clone,

including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Monoclonal antibodies useful with the present disclosure can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. The antibodies of the disclosure include chimeric, primatized, humanized, or human antibodies.

[0050] The antibodies produced utilizing the methods and compositions of the disclosure can be chimeric antibodies. The term “chimeric” antibody as used herein refers to an antibody having variable sequences derived from a non-human immunoglobulin, such as rat or mouse antibody, and human immunoglobulin constant regions, typically chosen from a human immunoglobulin template. Methods for producing chimeric antibodies are known in the art. See, *e.g.*, Morrison, 1985, *Science* 229(4719):1202-7; Oi *et al.*, 1986, *BioTechniques* 4:214-221; Gillies *et al.*, 1985, *J. Immunol. Methods* 125:191-202; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397.

[0051] The antibodies produced utilizing the methods and compositions of the disclosure can be humanized. “Humanized” forms of non-human (*e.g.*, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other target-binding subdomains of antibodies) which contain minimal sequences derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin consensus sequence. Methods of antibody humanization are known in the art. See, *e.g.*, Riechmann *et al.*, 1988, *Nature* 332:323-7; U.S. Patent Nos: 5,530,101; 5,585,089; 5,693,761; 5,693,762; and 6,180,370 to Queen *et al.*; EP239400; PCT publication WO 91/09967; U.S. Patent No. 5,225,539; EP592106; EP519596; Padlan, 1991, *Mol. Immunol.*, 28:489-498; Studnicka *et al.*, 1994, *Prot. Eng.* 7:805-814; Roguska *et al.*, 1994, *Proc. Natl. Acad. Sci.* 91:969-973; and U.S. Patent No. 5,565,332.

[0052] The antibodies produced utilizing the methods and compositions of the disclosure can be human antibodies. Completely “human” antibodies can be desirable for therapeutic treatment of human patients. As used herein, “human antibodies” include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins. Human antibodies can be made by a variety of methods known in the art including

phage display methods using antibody libraries derived from human immunoglobulin sequences. See U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. See, *e.g.*, PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598.

In addition, companies such as Medarex (Princeton, NJ), Astellas Pharma (Deerfield, IL), and Regeneron (Tarrytown, NY) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above. Completely human antibodies that recognize a selected epitope can be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, *e.g.*, a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers *et al.*, 1988, *Biotechnology* 12:899-903).

[0053] The antibodies produced utilizing the methods and compositions of the disclosure can be primatized. The term “primatized antibody” refers to an antibody comprising monkey variable regions and human constant regions. Methods for producing primatized antibodies are known in the art. See *e.g.*, U.S. Patent Nos. 5,658,570; 5,681,722; and 5,693,780.

[0054] The antibodies produced utilizing the methods and compositions of the disclosure can be bispecific antibodies. Bispecific antibodies are monoclonal, often human or humanized, antibodies that have binding specificities for at least two different antigens.

[0055] The antibodies produced utilizing the methods and compositions of the disclosure include derivatized antibodies. For example, but not by way of limitation, derivatized antibodies are typically modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, *etc.* Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, *etc.* Additionally, the derivative can contain one or more non-natural amino acids, *e.g.*, using ambrix technology (see, *e.g.*, Wolfson, 2006, *Chem. Biol.* 13(10):1011-2).

[0056] In yet another embodiment of the disclosure, the antibodies or fragments thereof can be antibodies or antibody fragments whose sequence has been modified to alter at least one constant region-mediated biological effector function relative to the corresponding wild type sequence.

[0057] For example, in some embodiments, an antibody of the disclosure can be modified to reduce at least one constant region-mediated biological effector function relative to an unmodified antibody, *e.g.*, reduced binding to the Fc receptor (FcR). FcR binding can be reduced by mutating the immunoglobulin constant region segment of the antibody at particular regions necessary for FcR interactions (see *e.g.*, Canfield and Morrison, 1991, J. Exp. Med. 173:1483-1491; and Lund *et al.*, 1991, J. Immunol. 147:2657-2662).

[0058] In other embodiments, the antibodies produced utilizing the methods and compositions of the disclosure modified to acquire or improve at least one constant region-mediated biological effector function relative to an unmodified antibody, *e.g.*, to enhance FcγR interactions (See, *e.g.*, US 2006/0134709). For example, an antibody with a constant region that binds FcγRIIA, FcγRIIB and/or FcγRIIIA with greater affinity than the corresponding wild type constant region can be produced according to the methods described herein.

[0059] Examples of antibodies that can be produced using methods of the present disclosure include, but are not limited to adalimumab, elotuzumab, enavatuzumab, daclizumab, voloxicimab, tositumomab, trastuzumab, istekinumab, abcicimab, besilesomab, etaracizumab, pemtumomab, omalizumab, pertuzumab, natalizumab, sulesomab, tefibazumab, votumumab, motavizumab, oregovomabm, panitumumab, zalutumumab, igovomab, bevacizumab, basiliximab, atlizumab, bectumomab, belimumab, alemtuzumab, nimotuzumab, mepolizumab, altumomab, ranibizumab, rituximab, palivizumab, gemtuzumab, golimumab, fontolizumab, nofetumomab, ofatumumab, arcitumomab, cetuximab, imciromab, certolizumab, rovelizumab, ruplizumab, ipilimumab, labetuzumab, catumaxomab, canakinumab, denosumab, eculizumab, fanolesomab, efalizumab, infliximab, edrecolomab, cfungumab, girentuximab, ertumaxomab and tocilizumab.

5.2.2. Other Glycoproteins

[0060] The methods of the disclosure can be used to produce glycoproteins of any protein, including proteins for therapeutic purposes. Examples of proteins that can be produced in accordance with the present disclosure include, but are not limited to growth factors such as erythropoietin (EPO), human chronic gonadotropin (hCG), granulocyte colony-stimulating factor (GCSF), antithrombin III, interleukin 1, interleukin 2, interleukin 6, human chorionic gonadotropin (hCG), antitrombin III, interferon alpha, interferon beta, interferon gamma, coagulation factors such as factor VIII, factor IX and human protein

C, epidermal growth factor, growth hormone-releasing factor, epidermal growth factor, angiostatin, vascular endothelial growth factor-2 and plasminogen activator.

5.3. Nucleic Acids and Expression Systems

[0061] Standard recombinant DNA methodologies such as those described in Molecular Cloning; A Laboratory Manual, Second Edition (Sambrook, Fritsch and Maniatis (eds), Cold Spring Harbor, N. Y., 1989), Current Protocols in Molecular Biology (Ausubel, F.M. *et al.*, eds., Greene Publishing Associates, 1989) and in U.S. Patent No. 4,816,397 can be used to produce recombinant mammalian cells suitable for producing glycoproteins in accordance with methods of the disclosure.

[0062] Glycoprotein sequences are well-known to those of skill in the art. In embodiments where the glycoprotein is an antibody, recombinant techniques can be used to obtain antibody heavy and light chain genes, incorporate these genes into recombinant expression vectors and introduce the vectors into host cells. To express an antibody recombinantly, a host cell is transfected with one or more recombinant expression vectors carrying DNA fragments encoding the immunoglobulin light and heavy chains of the antibody such that the light and heavy chains are expressed in the host cell and, optionally, secreted into the medium in which the host cells are cultured, from which medium the antibodies can be recovered. To generate nucleic acids encoding antibodies, DNA fragments encoding the light and heavy chain variable regions are first obtained. These DNAs can be obtained by amplification and modification of germline DNA or cDNA encoding light and heavy chain variable sequences, for example using the polymerase chain reaction (PCR). Germline DNA sequences for human heavy and light chain variable region genes are known in the art (See *e.g.*, the "VBASE" human germline sequence database; see also Kabat, E. A. *et al.*, 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Tomlinson *et al.*, 1992, J. Mol. Biol. 22T:116-198; and Cox *et al.*, 1994, Eur. J. Immunol. 24:827-836).

A DNA fragment encoding the heavy or light chain variable region of the antibody can be synthesized and used as a template for mutagenesis to generate a variant as described herein using routine mutagenesis techniques; alternatively, a DNA fragment encoding the variant can be directly synthesized.

[0063] Once DNA fragments encoding the antibody are obtained, these DNA fragments can be further manipulated by standard recombinant DNA techniques, for example to convert the variable region genes to full-length antibody chain genes, to Fab fragment genes or to a scFv gene. In these manipulations, a VL- or VH-encoding DNA fragment is operatively linked to another DNA fragment encoding another protein, such as an antibody constant region or a flexible linker. The term "operatively linked," as used in this context, is intended to mean that the two DNA fragments are joined such that the amino acid sequences encoded by the two DNA fragments remain in-frame.

[0064] The isolated DNA encoding the VH region can be converted to a full-length heavy chain gene by operatively linking the VH-encoding DNA to another DNA molecule encoding heavy chain constant regions (CH₁, CH₂, CH₃ and, optionally, CH₄). The sequences of human heavy chain constant region genes are known in the art (see *e.g.*, Kabat, E.A., *et al.*, 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments encompassing these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgG₁, IgG₂, IgG₃, IgG₄, IgA, IgE, IgM or IgD constant region, but in certain embodiments is an IgG₁ or IgG₄ constant region. For a Fab fragment heavy chain gene, the VH-encoding DNA can be operatively linked to another DNA molecule encoding only the heavy chain CH₁ constant region.

[0065] The isolated DNA encoding the VL region can be converted to a full-length light chain gene (as well as a Fab light chain gene) by operatively linking the VL-encoding DNA to another DNA molecule encoding the light chain constant region, CL. The sequences of human light chain constant region genes are known in the art (See *e.g.*, Kabat, E. A., *et al.*, 1991, Sequences of Proteins of Immunological Interest, Fifth Edition (U.S. Department of Health and Human Services, NIH Publication No. 91-3242)) and DNA fragments encompassing these regions can be obtained by standard PCR amplification. The light chain constant region can be a kappa or lambda constant region, but in certain embodiments is a kappa constant region. To create a scFv gene, the VH- and VL-encoding DNA fragments are operatively linked to another fragment encoding a flexible linker, *e.g.*, encoding the amino acid sequence (Gly₄~Ser)₃ (SEQ ID NO:21), such that the VH and VL sequences can be expressed as a contiguous single-chain protein, with the VL and VH regions joined by the flexible linker (See *e.g.*, Bird *et al.*, 1988, Science 242:423-426; Huston *et al.*, 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; McCafferty *et al.*, 1990, Nature 348:552-554).

[0066] To express glycoproteins, DNAs encoding the glycoprotein are inserted into expression vectors such that the genes are operatively linked to transcriptional and translational control sequences. In this context, the term “operatively linked” is intended to mean that a glycoprotein encoding a nucleic acid is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the glycoprotein coding sequence. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. Where the glycoprotein is an antibody, the light chain gene and the antibody heavy chain gene can be inserted into separate vectors or, more typically, both genes are inserted into the same expression vector.

[0067] The glycoprotein encoding nucleic acids can be inserted into the expression vector by standard methods (*e.g.*, ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present). Where the glycoprotein is an antibody, prior to insertion of the antibody light or heavy chain sequences, the expression vector can already carry antibody constant region sequences. For example, one approach to converting the antibody VH and VL sequences to full-length antibody genes is to insert them into expression vectors already encoding heavy chain constant and light chain constant regions, respectively, such that the VH segment is operatively linked to the CH segment(s) within the vector and the VL segment is operatively linked to the CL segment within the vector. Additionally or alternatively, the recombinant expression vector can encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene can be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the antibody chain gene. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (*i.e.*, a signal peptide from a non-immunoglobulin protein).

[0068] The recombinant expression vectors can carry regulatory sequences that control the expression of the glycoprotein coding sequences in a host cell. The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185 (Academic Press, San Diego, CA, 1990). It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, *etc.* Suitable regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (*e.g.*, the adenovirus major late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and sequences thereof, see *e.g.*, U.S. Patent No. 5,168,062 by Stinski, U.S. Patent No. 4,510,245 by Bell *et al.*, and U.S. Patent No. 4,968,615 by Schaffner *et al.*

[0069] The recombinant expression vectors can carry additional sequences, such as sequences that regulate replication of the vector in host cells (*e.g.*, origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see *e.g.*, U.S. Patents Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel *et al.*). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Suitable selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in DHFR⁻ host cells with methotrexate

selection/amplification) and the neo gene (for G418 selection). For expression of the light and heavy chains, the expression vector(s) encoding the heavy and light chains is transfected into a host cell by standard techniques. The various forms of the term “transfection” are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a mammalian host cell.

[0070] The glycoproteins of the disclosure can be expressed in mammalian host cells, for optimal secretion of a properly folded and immunologically active protein. Exemplary mammalian host cells for expressing the recombinant antibodies of the disclosure include Chinese Hamster Ovary (CHO cells) (including DHFR⁻ CHO cells, described in Urlaub and Chasin, 1980, Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, *e.g.*, as described in Kaufman and Sharp, 1982, Mol. Biol. 159:601-621), NSO myeloma cells, COS cells, SP2/0 cells, EB66® cells, and PER.C6® cells. When recombinant expression vectors encoding glycoproteins are introduced into mammalian host cells, the glycoproteins are produced by culturing the host cells for a period of time sufficient to allow for expression of the glycoprotein in the host cells or secretion of the glycoprotein into the culture medium in which the host cells are grown. Suitable culturing techniques are described in Section 5.4. Glycoproteins can be recovered from the culture medium using standard protein purification methods, for example, as described in Section 5.5.

5.4. Culture Methods

[0071] The disclosure provides methods for producing glycoproteins (*e.g.*, antibodies) by culturing mammalian cells engineered to express the glycoproteins in a high glycine culture medium, such as a culture medium described in Section 5.1. Methods of the disclosure provide glycoproteins with reduced fucosylated glycoforms as compared to glycoproteins produced in traditional culture media.

[0072] The recombinant mammalian cells described in Section 5.3 can be cultured in suspension, such as by shake flask cultivation in small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the glycoprotein to be expressed and/or isolated. Alternatively, the mammalian cells can be cultured while attached to a solid substrate.

[0073] In particular embodiments, the recombinant mammalian cells are added to the basal medium at an initial cell density in the range of $0.5 - 5 \times 10^5$ cells/mL and more typically in the range of $1.5 - 2.5 \times 10^5$ cells/mL. The cultures are generally harvested for approximately 8 days to 20 days following inoculation, and more typically between 10 days to 14 days following inoculation.

[0074] Following inoculation of the mammalian cells, the growth of the cells can be promoted by addition of nutrients according to a pre-determined feeding schedule. Addition of the feed medium to the

culture can be through processes known in the art such as continuous culture, batch culture and fed-batch culture. To support the propagation of cells, a feed solution can be added to the culture at intermittent times following inoculation. As used herein, the term “feed” refers to nutrients added to the culture after inoculation. The term “feed solution” or “feed media” refers to a solution containing feed that is added to the culture following inoculation.

5.5. Recovery and Purification

[0075] Techniques for recovering and purifying expressed protein are well known in the art and can be tailored to the particular glycoprotein(s) being expressed by the recombinant mammalian cell.

Glycoproteins can be recovered from the culture medium and or cell lysates. In embodiments where the method is directed to producing a secreted glycoprotein, the glycoprotein can be recovered from the culture medium. Proteins may be recovered or purified from culture media by a variety of procedures known in the art including but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The recovered glycoprotein may then be further purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing (IEF), differential solubility (*e.g.*, ammonium sulfate precipitation), or extraction (see, *e.g.*, Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

[0076] In embodiments where the glycoprotein is an antibody, the antibody can be purified by a process that utilizes Protein A affinity chromatography in conjunction with strong anion exchange (Q-Sepharose) chromatography and weak cation exchange (CM-650M) chromatography, permitting continuous flow processing without dilution of process intermediate. This method for obtaining purified antibody can entail the following steps:

- (i) protein A affinity chromatography to isolate antibody from other cell culture components;
- (ii) low pH viral inactivation;
- (iii) strong anion exchange chromatography to remove DNA;
- (iv) weak cation exchange chromatography to reduce aggregates; and
- (v) filtration to remove viruses.

Steps (ii) – (v) can be carried out in any order.

[0077] Once isolated, an antibody can, if desired, be further purified, *e.g.*, by high performance liquid chromatography (see, *e.g.*, Fisher, Laboratory Techniques In Biochemistry And Molecular Biology (Work

and Burdon, eds., Elsevier, 1980), or by gel filtration chromatography on a Superdex™ 75 column (Pharmacia Biotech AB, Uppsala, Sweden).

5.6. Protein Glycoforms

[0078] Post-translational modification of a protein by glycosylation can influence the biochemical and physical properties of the protein. For instance, the properties of an antibody can be influenced by the glycosylation at both the Fc and the Fab regions of the antibody. “Glycosylation” refers to the covalent modification of proteins (*e.g.*, antibodies) with carbohydrates (*e.g.*, oligosaccharide chains). Typical sugars in glycoproteins include mannose, glucose, galactose, fucose, N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), and sialic acid.

[0079] The individual glycosylated molecules (*e.g.*, glycosylated antibodies) are referred to herein as glycoforms. The “glycosylation profile” refers to the set of glycoforms in a particular sample. Glycosylation generally refers to N-linked glycosylation or O-linked glycosylation. The term “N-linked glycosylation” refers to the covalent linkage of an oligosaccharide chain to an asparagine residue of a protein, thereby forming N-linked oligosaccharides. N-linked oligosaccharides are also referred to as N-linked glycans. The term “O-linked glycosylation” refers to the covalent linkage of an oligosaccharide chain to the hydroxyl group of a serine or threonine residue of a protein, thereby forming O-linked oligosaccharides. O-linked oligosaccharides are also referred to as O-linked glycans.

[0080] N-linked glycans are further characterized by the number of galactose residues at their terminal ends, whether or not they contain a fucose attached to the N-linked-N-acetyl glucosamine. N-linked glycans that have a fucose molecule attached to the N-linked N-acetyl glucosamine are referred to herein as fucosylated N-linked glycans. Proteins with fucosylated N-linked glycans are referred to herein as fucosylated glycoforms. The characteristics of four different fucosylated N-linked glycans are listed below (also see **FIGURE 1**):

- G0: Biantennary (*i.e.*, having two antennas) core structure with fucose attached to the N-linked N-acetyl glucosamine and one N-acetyl glucosamine on each branch of the core structure.
- G1: Biantennary core structure with fucose attached to the N-linked N-acetyl glucosamine, one N-acetyl glucosamine on each branch of the core structure and terminal galactose on one branch of the core structure.
- G2: Biantennary core structure with fucose attached to the N-linked N-acetyl glucosamine, one N-acetyl glucosamine and one terminal galactose on each branch of the core structure.

- G0-GlcNAc: Biantennary core structure with fucose attached to the N-linked N-acetyl glucosamine, one N-acetyl glucosamine on one branch of the core structure and no terminal galactose.

[0081] N-linked glycans that do not contain a fucose molecule are referred to as non-fucosylated glycans. Proteins with non-fucosylated glycans are referred to as non-fucosylated glycoforms. For instance, a G0-GlcNAc-Fucose N-linked glycan has a biantennary core structure without fucose attached to the N-linked N-acetyl glucosamine, one N-acetyl glucosamine on one branch of the core structure and no terminal galactose. An antibody containing a G0-GlcNAc-Fucose N-linked glycan is referred to herein as a G0-GlcNAc-Fucose N-linked glycoform.

[0082] N-linked glycosylation profiles can be assessed by various methods. For example, N-linked glycosylation profiles can be assessed by digesting the antibody with trypsin and analyzing the resulting peptide mixture using reverse-phase chromatography with mass spectrometric detection and quantitation of the various glycopeptides. In a specific method, the digested peptides are analyzed using a YMC-Pack ODS-AQ, 5 μ m particle size, 120 Angstrom pore size, 2.0 mm x 250 mm reverse phase column (YMC Co., Ltd, catalog number AQ12S05-2502WT) and the eluted peptides are detected and quantified using a Thermo LCQ Deca XP+ mass spectrometer (Thermo Finnigan). The relative abundance of each glycoform is determined based on the mass spectrometric extracted ion chromatogram peak area of the corresponding glycopeptides relative to the sum of the peak areas of all observed glycopeptides.

[0083] Alternatively, N-linked glycosylation profiles can be assessed by cleaving the N-linked oligosaccharides with amidase PNGase F, derivatizing the oligosaccharides with a fluorescent label and analyzing the resultant mixture via normal phase HPLC with fluorescent detection. In a specific method, derivatized, cleaved N-linked glycans are resolved at 50°C on a 250 x 4.6 mm polymeric-amine bonded Asahipak Amino NH₂P-504E column (5 μ m particle size, Phenomenex, cat. No. CHO-2628).

[0084] Studies of the glycosylation profile of IgG have revealed that IgG carries at least 30 different N-linked oligosaccharides. See Dwek *et al.*, 1995, J. Anat. 187:279-292. N-linked glycosylation sites are found on both the Fc region and the Fab regions of many antibodies. N-linked oligosaccharides without any sialic acid groups are often referred to as neutral N-linked oligosaccharides. N-linked oligosaccharides with one or two sialic acid groups at the non-reducing sugar terminus of the oligosaccharide are referred to as monosialylated or disialylated N-linked oligosaccharides, respectively. With respect to IgG, Fc glycosylation is characterized by a low incidence of monosialylated and disialylated structures while Fab glycosylation is characterized by a high incidence of monosialylated and disialylated structures.

[0085] Additional N-linked glycans have been identified in the Fc region of antibodies. For instance, glycans containing high amounts of mannose characterized by glycans that only contain two N-acetyl glucosamines with the remaining residues containing mannose are referred to as “high mannose glycans”. The mannose residues are covalently attached to a GlcNAc at the 2-position of the oligosaccharide. One example of a high mannose five glycan is “Mannose5 glycan”. Mannose 5 glycans contain five mannose residues. Proteins with Mannose5 glycans are referred to herein as “Mannose5 glycoforms”. The high mannose glycans are examples of non-fucosylated glycans.

[0086] The present disclosure provides methods of producing antibodies enriched in glycoforms not containing fucose (*i.e.*, non-fucosylated glycoforms). Examples of non-fucosylated glycoforms include, but are not limited to G0-GlcNAc- Fucose glycoforms and Mannose5 glycoforms. Antibodies lacking fucose have been correlated with enhanced ADCC (antibody-dependent cellular cytotoxicity) activity. Lymphocytes, particularly Natural Killer (NK) cells, contain surface-bound receptors that are capable of binding to the Fc region of antibodies. For instance, the human CD16a receptor on NK cells binds to the Fc region of an antibody bound to a target cell, thereby initiating killing of the target cell. Without being bound by theory, it is believed that non-fucosylated glycoforms produced in accordance with methods of the present disclosure display higher binding affinity to the CD16a receptor on NK cells than glycoforms containing fucose (*i.e.*, fucosylated glycoforms), which is responsible for the increased ADCC activity.

[0087] Antibodies produced in high glycine media as described herein contain significantly more non-fucosylated glycoforms than antibodies produced in conventional media. As described in Section 5.3, the total amount of glycans lacking fucose generally increases as the concentration of glycine in the culture medium increases from 2 mM to 30 mM. In particular, the percentage of G0-GlcNAc-Fucose and Mannose5 glycans increase when NS0 cells are cultured in the culture media produced in accordance with the present disclosure. While the amount of non-fucosylated antibodies produced in culture media of the present disclosure is dependent on the AOI, the percentage increase of glycans lacking fucose is generally at least 120% relative to antibodies produced in conventional media (*i.e.*, media with glycine concentrations of 2 mM or less). For instance, the percent increase of total glycans lacking fucose on antibodies produced in culture media of the present disclosure can be 120%, 150%, 180%, 200%, 250%, 300% or 400% relative to antibodies produced in conventional media. In specific embodiments, the percent increase of total glycans lacking fucose on antibodies produced by methods of the disclosure relative to antibodies produced in conventional basal media be bounded by any of the two foregoing values, such as, but not limited to, 120-150%, 150-180%, 150-200%, or 200-300%.

[0088] The present disclosure further provides compositions comprising particular antibodies of interest with altered glycosylation profiles relative to antibodies produced in conventional media. In particular,

the antibodies produced by the methods of the present disclosure have a greater percentage of non-fucosylated glycoforms than antibodies produced in conventional media. As a result, antibodies produced by methods of the present disclosure generally display higher ADCC activity than antibodies produced in conventional media and show higher binding to the CD16a receptor on NK cells.

[0089] In one particular embodiment, the methods of the present disclosure can be used to produce a monoclonal antibody having a VH region of the amino acid sequence SEQ ID NO:1 and a VL region of the amino acid sequence SEQ ID NO:2. The monoclonal antibody, referred to as elotuzumab (HuLuc 63), was disclosed in U.S. Patent Publication No. 2006/0024296 as having VH and VL regions of SEQ ID NO:41 and SEQ ID NO:44, respectively.

Elotuzumab has a full heavy chain amino acid sequence of SEQ ID NO:3 and a full light chain amino acid sequence of SEQ ID NO:4. Elotuzumab exhibits *in vitro* antibody-dependent cellular cytotoxicity (ADCC) in primary myeloma cells and *in vivo* anti-tumor activity (Hsi *et al.*, (2008) Clin. Cancer Res. 14(9):2775).

[0090] The disclosure provides a composition comprising a population of elotuzumab molecules, wherein at least 4% of the glycans lack fucose, which is produced in accordance with the cell culturing process of the present disclosure. For instance, at least 4%, at least 5%, at least 6%, at least 7% or at least 8% of the glycans on elotuzumab lack fucose. In particular embodiments, the non-fucosylated glycans of elotuzumab produced in accordance with the cell culturing process of the present disclosure include, but are not limited to N-linked glycans such as G0-GlcNAC-Fucose and Mannose5 glycans. In these embodiments, at least 4% of the N-linked glycans lack fucose. In other embodiments, the disclosure provides elotuzumab molecules having at least 2.5% of the total glycans present as Mannose5 glycans. For instance, at least 3%, at least 4% or at least 5% of the glycans on elotuzumab can be present as Mannose5 glycans.

[0091] In another embodiment, the methods of the present disclosure can be used to produce a monoclonal antibody having a VH region of the amino acid sequence SEQ ID NO:5 and a VL region of the amino acid sequence SEQ ID NO:6. The monoclonal antibody, referred to as daclizumab, is a humanized IgG₁ antibody that specifically binds the alpha subunit (also referred to as CD25 or Tac) of the human interleukin-2 receptor (IL-2R), which is an important mediator of lymphocyte activation. Daclizumab has a full heavy chain amino acid sequence of SEQ ID NO:7 and a full light chain amino acid sequence of SEQ ID NO:8.

[0092] The disclosure provides a composition comprising a population of daclizumab molecules, wherein at least 3% of glycans lack fucose, which is produced in accordance with the cell culturing process of the present disclosure. For instance, at least 3%, at least 4%, at least 5%, at least 6%, at least

7% or at least 8% of the glycans on daclizumab lack fucose. In particular embodiments, the non-fucosylated glycans of daclizumab produced in accordance with the cell culturing process of the present disclosure include, but are not limited to N-linked glycans such as G0-GlcNAc-Fucose and Mannose5 glycans. In these embodiments, at least 3% of the N-linked glycans lack fucose. In other embodiments, the disclosure provides daclizumab molecules having at least 2 % of the total glycans present as Mannose5 glycans. For instance, at least 3%, at least 4% or at least 5% of the glycans on daclizumab can be present as Mannose5 glycans.

[0093] In another embodiment, the methods of the present disclosure can be used to produce a monoclonal antibody having a VH region of the amino acid sequence SEQ ID NO:9 and a VL region of the amino acid sequence SEQ ID NO:10. The monoclonal antibody, referred to as voloxicimab, is a high-affinity IgG4 chimeric (82% human, 18% murine) monoclonal antibody (mAb) that specifically binds to $\alpha_5\beta_1$ integrin used for the treatment of a variety of advanced stage tumors. Voloxicimab has a full heavy chain amino acid sequence of SEQ ID NO:11 and a full light chain amino acid sequence of SEQ ID NO:12.

[0094] The disclosure provides a composition comprising a population of voloxicimab molecules, wherein at least 1% of the glycans lack fucose, which is produced in accordance with the cell culturing process of the present disclosure. For instance, at least 1% of the glycans on voloxicimab lack fucose. In particular embodiments, the non-fucosylated glycans of voloxicimab produced in accordance with the cell culturing process of the present disclosure include, but are not limited to N-linked glycans such as G0-GlcNAc-Fucose and Mannose5 glycans. In these embodiments, at least 1% of the N-linked glycans lack fucose. In other embodiments, the disclosure provides voloxicimab molecules having at least 0.5% of the total glycans present as Mannose5 glycans.

[0095] In another embodiment, the methods of the present disclosure can be used to produce a monoclonal antibody having a VH region of the amino acid sequence SEQ ID NO:13 and a VL region of the amino acid sequence SEQ ID NO:14. The monoclonal antibody, referred to as PDL241, is a humanized IgG₁ antibody that binds to the protein CS1 (but at a different epitope than elotuzumab). PDL241 has a full heavy chain amino acid sequence of SEQ ID NO:15 and a full light chain amino acid sequence of SEQ ID NO:16.

[0096] The disclosure provides a composition comprising a population of PDL241 molecules, wherein at least 14% of the glycans lack fucose, which is produced in accordance with the cell culturing process of the present disclosure. For instance, at least 14%, at least 15%, at least 16%, at least 17%, at least 18% or at least 19% of the glycans on PDL241 lack fucose. In particular embodiments, the non-fucosylated glycans of PDL241 produced in accordance with the cell culturing process of the present disclosure

include, but are not limited to N-linked glycans such as G0-GlcNAC-Fucose and Mannose5 glycans. In these embodiments, at least 14% of the N-linked glycans lack fucose. In other embodiments, the disclosure provides PDL241 molecules having at least 8 % of the total glycans present as Mannose5 glycans. For instance, at least 9%, at least 10%, at least 11% or at least 12% of the glycans on PDL241 can be present as Mannose5 glycans.

[0097] In another embodiment, the methods of the present disclosure can be used to produce a monoclonal antibody having a VH region of the amino acid sequence SEQ ID NO:17 and a VL region of the amino acid sequence SEQ ID NO:18. The monoclonal antibody, referred to as enavatuzumab (PDL192) is a humanized IgG1 antibody to TweakR that exhibits anti-tumor activity in preclinical models through two mechanisms: direct signaling through TweakR and antibody-dependent cellular cytotoxicity. Enavatuzumab has a full heavy chain amino acid sequence of SEQ ID NO:19 and a full light chain amino acid sequence of SEQ ID NO:20.

[0098] The disclosure provides a composition comprising a population of enavatuzumab molecules, wherein at least 5% of the glycans lack fucose, which is produced in accordance with the cell culturing process of the present disclosure. For instance, at least 5%, at least 6%, at least 7%, at least 8%, at least 9% or at least 10% of the glycans on enavatuzumab lack fucose. In particular embodiments, the non-fucosylated glycans of enavatuzumab produced in accordance with the cell culturing process of the present disclosure include, but are not limited to N-linked glycans such as G0-GlcNAC-Fucose and Mannose5 glycans. In these embodiments, at least 5% of the N-linked glycans lack fucose. In other embodiments, the disclosure provides enavatuzumab molecules having at least 2.5% of the total glycans present as Mannose5 glycans. For instance, at least 3%, at least 4% or at least 5% of the glycans on enavatuzumab can be present as Mannose5 glycans.

[0099] Table 7 below provides the sequences of elotuzumab, daclizumab, voloximab, PDL241 and enavatuzumab as identified above.

TABLE 7		
SEQ ID NO.	Description	Sequence
1	Elotuzumab heavy chain variable region	EVQLVESGGGLVQPGGSLRLSCAASGDFSRYSWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGLTVTVSS
2	Elotuzumab light chain variable region	DIQMTQSPSSLSASVGDRTITCKASQDVGIATAWYQQKPKVPLKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQYSSYPYTFGQGTKVEIK
3	Elotuzumab heavy chain full sequence	MDFGLIFFIVALLKGVCQEVQLVESGGGLVQPGGSLRLSCAASGDFSRYSWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
4	Elotuzumab light chain full sequence	METHSQVFVYMLLWLSGVEGDIQMTQSPSSLSASVGDRTITCKASQDVGIATAWYQQKPKVPLKLLIYWASTRHTGVPDRFSGSGGTDFLTISSLQPEDVATYYCQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC
5	Daclizumab heavy chain variable region	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGLTLTVSS
6	Daclizumab light chain variable region	DIQMTQSPSTLSASVGDRTITCSASSISYMHWYQQKPKAPKLLIYTTSNLASGVPAREFSGSGSGTEFTLTISSLQPDDEATYYCHQRSTYPLTFGSGTKVEVKKR

TABLE 7

SEQ ID NO.	Description	Sequence
7	Daclizumab heavy chain full sequence	QVQLVQSGAEVKKPGSSVKVCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKF KDKATITADESTNTAYMELSSLRSEDTAVYFCARGGGVFDYWGQGTTLTVSSGSPVFLAPSSKST SGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICN VNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHQDWLNGKEYCKVSNKALPA PIEKTIKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPV LSDSGSFLLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
8	Daclizumab light chain full sequence	DIQMTQSPSTLSASVGDRTVTITCSASSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSG TEFTLTISLQPDDEAFATYYCHQRSTYPLTFSGSGTKVEKRTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQG LSSPVTKSFNR
9	Voloxicimab heavy chain variable region	QVQLKESGPGLVAPQSLSITCTISGFSLTDYGVHWVRQPPGKGLEWLVVIWSDGSSTYNSALKSR MTIRKDNSKSQVFLIMNSLQTDDSAMYCARHGTYYGMTTGTGALDYWGQGTSTVTVSS
10	Voloxicimab light chain variable region	QIVLTQSPAIMASLGERVTMTCTASSSVSSNYLHWYQQKPGSAPNLIWYSTSNLASGVPARFSGS GSGTSYSLTISSMEAEADAATYYCHQYLRSPPTFGGGTKLEIKR
11	Voloxicimab heavy chain full sequence	QVQLKESGPGLVAPQSLSITCTISGFSLTDYGVHWVRQPPGKGLEWLVVIWSDGSSTYNSALKSR MTIRKDNSKSQVFLIMNSLQTDDSAMYCARHGTYYGMTTGTGALDYWGQGTSTVTVSSASTKGP SVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPS SSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVT CVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQENSTYRVSVLTVLHQDWLNGKEYCKKV SNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFLLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLGK
12	Voloxicimab light chain full sequence	QIVLTQSPAIMASLGERVTMTCTASSSVSSNYLHWYQQKPGSAPNLIWYSTSNLASGVPARFSGS GSGTSYSLTISSMEAEADAATYYCHQYLRSPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNINFPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC

TABLE 7		
SEQ ID NO.	Description	Sequence
13	PDL241 heavy chain variable region	QVQLVQSGAEVKKPGASVKVCKASGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDDGDTKYNGK FKGKATLTADKSTSTAYMELSSLRSEDATVYYCARSTMIATGAMDYWGQGLTVTVSS
14	PD241 light chain variable region	DIQMTQSPSSLSASVGDRTTITCKASQDVSTAVAWYQQKPKAPKLLIYSASYRYTGVPRFTGSG SGTDFLTLSLQPEDFATYYCQHYSTPPYTFGGGTKVEIKR
15	PDL241 heavy chain full sequence	QVQLVQSGAEVKKPGASVKVCKASGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDDGDTKYNGK FKGKATLTADKSTSTAYMELSSLRSEDATVYYCARSTMIATGAMDYWGQGLTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS SLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELGGPSVFLFPPKPKDQLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNAKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGK
16	PDL241 light chain full sequence	DIQMTQSPSSLSASVGDRTTITCKASQDVSTAVAWYQQKPKAPKLLIYSASYRYTGVPRFTGSG SGTDFLTLSLQPEDFATYYCQHYSTPPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVV CLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC
17	Enavatuzumab heavy chain variable region	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMWVRQAPGKGLEWVAEIRLKSDNYATHYAE SVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYADAMDYWGQGLTVTVSS
18	Enavatuzumab light chain variable region	DIQMTQSPSSLSASVGDRTTITCRASQSVSTSSYSYMHWYQQKPKGAPKLLIKYASNLESQVPSRFS GSGSGTDFLTLSLQPEDFATYYCQHSWEIPYTFGGGTKVEIKR
19	Enavatuzumab heavy chain full sequence	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMWVRQAPGKGLEWVAEIRLKSDNYATHYAE SVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYADAMDYWGQGLTVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELGGPSVFLFPPKPKDQLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPGK

TABLE 7		
SEQ ID NO.	Description	Sequence
20	PDL241 light chain full sequence	DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESQVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSLYSLSSITLTLTKADYEEKHKVYACE VTHQGLSSPVTKSFNRGEC

Table 7: Sequences of elotuzumab, daclizumab, voloximab, PDL241 and enavatuzumab

5.7. Pharmaceutical Compositions

[0100] The glycoprotein compositions described above can be supplied as part of a sterile, pharmaceutical composition that includes a pharmaceutically acceptable carrier. This composition can be in any suitable form (depending upon the desired method of administering it to a patient). The glycoprotein compositions can be administered to a patient by a variety of routes such as orally, transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intrathecally, topically or locally. The most suitable route for administration in any given case will depend on the particular glycoprotein, the subject, and the nature and severity of the disease and the physical condition of the subject. Typically, the glycoprotein compositions will be administered intravenously or subcutaneously.

[0101] Pharmaceutical compositions can be conveniently presented in unit dose forms containing a predetermined amount of a glycoprotein composition of the disclosure per dose. Such a unit can contain for example but without limitation 0.5 mg to 5 g, for example 10 mg to 1 g, or 20 to 50 mg. Pharmaceutically acceptable carriers for use in the disclosure can take a wide variety of forms depending, *e.g.*, on the condition to be treated or route of administration.

[0102] Therapeutic formulations of the glycoprotein compositions of the disclosure can be prepared for storage as lyophilized formulations or aqueous solutions by mixing the glycoprotein having the desired degree of purity with optional pharmaceutically-acceptable carriers, excipients or stabilizers typically employed in the art (all of which are referred to herein as “carriers”), *i.e.*, buffering agents, stabilizing agents, preservatives, isotonifiers, non-ionic detergents, antioxidants, and other miscellaneous additives. See, Remington’s Pharmaceutical Sciences, 16th edition (Osol, ed. 1980). Such additives must be nontoxic to the recipients at the dosages and concentrations employed.

[0103] Buffering agents help to maintain the pH in the range which approximates physiological conditions. They can be present at concentration ranging from about 2 mM to about 50 mM. Suitable buffering agents for use with the present disclosure include both organic and inorganic acids and salts thereof such as citrate buffers (*e.g.*, monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, *etc.*), succinate buffers (*e.g.*, succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, *etc.*), tartrate buffers (*e.g.*, tartaric acid-sodium tartrate mixture, tartaric acid-potassium

tartrate mixture, tartaric acid-sodium hydroxide mixture, *etc.*), fumarate buffers (*e.g.*, fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, *etc.*), gluconate buffers (*e.g.*, gluconic acid-sodium glyconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium glyconate mixture, *etc.*), oxalate buffer (*e.g.*, oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, *etc.*), lactate buffers (*e.g.*, lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, *etc.*) and acetate buffers (*e.g.*, acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, *etc.*). Additionally, phosphate buffers, histidine buffers and trimethylamine salts such as Tris can be used.

[0104] Preservatives can be added to retard microbial growth, and can be added in amounts ranging from 0.2%-1% (w/v). Suitable preservatives for use with the present disclosure include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalconium halides (*e.g.*, chloride, bromide, and iodide), hexamethonium chloride, and alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol. Isotonicifiers sometimes known as “stabilizers” can be added to ensure isotonicity of liquid compositions of the present disclosure and include polyhydric sugar alcohols, for example trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol. Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the therapeutic agent or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, *etc.*, organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols such as inositol; polyethylene glycol; amino acid polymers; sulfur containing reducing agents, such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, α -monothioglycerol and sodium thio sulfate; low molecular weight polypeptides (*e.g.*, peptides of 10 residues or fewer); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophylic polymers, such as polyvinylpyrrolidone monosaccharides, such as xylose, mannose, fructose, glucose; disaccharides such as lactose, maltose, sucrose and trisaccharides such as raffinose; and polysaccharides such as dextran. Stabilizers can be present in the range from 0.1 to 10,000 weights per part of weight active protein.

[0105] Non-ionic surfactants or detergents (also known as “wetting agents”) can be added to help solubilize the glycoprotein as well as to protect the glycoprotein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stressed without causing denaturation of the protein. Suitable non-ionic surfactants include polysorbates (20, 80, *etc.*), polyoxamers (184, 188 *etc.*), Pluronic polyols, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, *etc.*). Non-ionic surfactants can be present in a range of about 0.05 mg/ml to about 1.0 mg/ml, for example about 0.07 mg/ml to about 0.2 mg/ml.

[0106] Additional miscellaneous excipients include bulking agents (*e.g.*, starch), chelating agents (*e.g.*, EDTA), antioxidants (*e.g.*, ascorbic acid, methionine, vitamin E), and cosolvents.

5.8. Methods of Treatment

5.8.1. Elotuzumab and PDL241 Compositions

[0107] The elotuzumab and PDL241 compositions described in Section 5.6 are useful for treating a variety of disorders and conditions thought to implicate increased expression of the protein CS1 on neoplastic cells, including, for example, multiple myeloma. Specific patient populations, formulations, modes of administration and dosage amounts and schedules useful for treating or preventing multiple myeloma are described in U.S. Patent No. 7,709,610. All of these formulations, modes of administration, dosing amounts and schedules, as well as disclosed specific patient populations and combination therapies, are equally suited to the elotuzumab and PDL241 compositions described herein.

[0108] The elotuzumab and PDL241 compositions and formulations described herein are administered in amounts that provide therapeutic benefit. Therapeutic benefit includes, but is not limited, to treatment of the underlying disorder. Therapeutic benefit may also include improving or ameliorating symptoms or side effects of a particular disease as assessed using standard diagnostic and other tests. For multiple myeloma, various means of assessing therapeutic benefit are described in U.S. Patent No. 7,709,610. All of these various tests can be used to assess therapeutic benefit in the context of patients suffering from multiple myeloma.

5.8.2. Voloxicimab Compositions

[0109] The voloxicimab compositions described in Section 5.6 are useful for treating a variety of disorders and conditions thought to implicate the $\alpha_5\beta_1$ integrin, including, for example, a variety of solid

tumors. Specific patient populations, formulations, modes of administration and dosage amounts and schedules useful for treating or preventing solid tumors, decreasing angiogenesis and curtailing cancer cell proliferation are described in U.S. Patent No. 7,662,384.

All of these formulations, modes of administration, dosing amounts and schedules, as well as disclosed specific patient populations and combination therapies, are equally suited to the voloxicimab compositions described herein.

[0110] The voloxicimab compositions and formulations described herein are administered in amounts that provide therapeutic benefit. Therapeutic benefit includes, but is not limited, to treatment of the underlying disorder. Therapeutic benefit may also include improving or ameliorating symptoms or side effects of a particular disease as assessed using standard diagnostic and other tests. For treatment of tumors, various means of assessing therapeutic benefit are described in U.S. Patent No. 7,662,384. All of these various tests can be used to assess therapeutic benefit in the context of patients suffering from cancer.

5.8.3. Enavatuzumab Compositions

[0111] The enavatuzumab compositions described in Section 5.6 are useful for treating a variety of disorders and conditions thought to implicate the Tweak Receptor (TweakR), including, for example, a variety of solid tumors. Specific patient populations, formulations, modes of administration and dosage amounts and schedules useful for treating or preventing solid tumors, decreasing angiogenesis and curtailing cancer cell proliferation are described in U.S. Published App. No. 2009/0074762.

All of these formulations, modes of administration, dosing amounts and schedules, as well as disclosed specific patient populations and combination therapies, are equally suited to the enavatuzumab compositions described herein.

[0112] The enavatuzumab compositions and formulations described herein are administered in amounts that provide therapeutic benefit. Therapeutic benefit includes, but is not limited, to treatment of the underlying disorder. Therapeutic benefit may also include improving or ameliorating symptoms or side effects of a particular disease as assessed using standard diagnostic and other tests. For treatment of tumors, various means of assessing therapeutic benefit are described in U.S. Published App. No. 2009/0074762. All of these various tests can be used to assess therapeutic benefit in the context of patients suffering from cancer.

6. EXAMPLES

[0113] Various aspects and features of the inventions described herein are described further by way of the examples, below. Features that are described in association with a particular embodiment (whether in the Summary above or in the examples that follow) can be deviated from without substantially affecting the desirable properties of the methods and compositions of the disclosure, and moreover that different embodiments can be combined and used in various ways together unless they are clearly mutually exclusive. Accordingly, it is to be understood that the examples provided below are intended to be illustrative and not limiting, and should not be construed as limiting the claims that follow.

6.1. Production of NS0 Stable Cell Lines

6.1.1. Elotuzumab

[0114] Mouse myeloma cell line NS0-W (W indicates that the NS0 cells were weaned from their requirement for serum and cholesterol) as described by Hartman *et al.*, 2007, Biotechnol. Bioeng. 96(2):294-306, was maintained in a protein-free basal medium. NS0-W cells were transfected with pHuLuc63 expression plasmid DNA by electroporation. Transfectants that had stably integrated the expression plasmid were selected in the presence of mycophenolic acid in DMEM medium containing 10% fetal bovine serum. Starting from an NS0-W transfectant that produced a high level of HuLuc63, subcloning was performed by limited dilution. A subclone with acceptable productivity and product characteristics was chosen as the final production cell line and designated 192-C17.

6.1.2. Daclizumab

[0115] Mouse myeloma cell line NS0 was obtained from European Collection of Cell Cultures (ECACC catalog # 85110503, Salisbury, Wiltshire, UK). A vial of these NS0 cells was thawed into DMEM supplemented with 10% FBS. The cells were subsequently cultured in basal medium SFM-3 supplemented with 1 mg/mL BSA. SFM-3 is a 1:1 mixture of DMEM and Ham's F-12 supplemented with 10 mg/L insulin and 10 ug/mL Transferrin. Over a period of approximately 3 months, the NS0 cells were adapted to SFM-3 without supplements, by gradually reducing the amount of FBS present in the culture medium until it was eliminated, and then finally removing BSA in a single step. The resulting host cell line was passaged 15-20 times in SFM-3 and a frozen bank was prepared.

[0116] The SFM-3 adapted cells were transfected with pHAT.IgG1.rg.dE by electroporation. Transfectants that had stably integrated the vector were selected in the presence of mycophenolic acid in

DMEM medium containing 10% fetal bovine serum. Starting from an NS0 stable transfectant that produced a high level of DAC HYP subcloning was performed by either limited dilution cloning or fluorescence activated cell sorting (FACS). A subclone with acceptable productivity and product characteristics was chosen as the final production cell line and designated 7A11-5H7-14-43.

6.1.3. Voloxicimab

[0117] The M200-producing cell line, 46-12, was derived from NS0-W cells transfected with the expression plasmid P-200M. Prior to transfection, NS0 cells, received from the ECACC (ECACC No. 85110503), were adapted to serum- and cholesterol-free conditions at PDL and designated NS0-W. NS0-W cells were transfected with P-200M expression plasmid DNA by electroporation. Transfectants that had stably integrated the expression plasmid were selected in the presence of mycophenolic acid in DMEM medium containing 5% fetal bovine serum. Starting from an NS0-W transfectant that produced a high level of M200, subcloning was performed by limited dilution cloning. A subclone with acceptable productivity and product characteristics was chosen as the final production cell line and designated 46-12.

6.1.4. PDL241

[0118] Mouse myeloma cell line NS0-W (W indicates that the NS0 cells were weaned from their requirement for serum and cholesterol) as described by Hartman *et al.*, 2007, Biotechnol. Bioeng. 96(2):294-306, was maintained in a protein-free basal medium. NS0-W cells were transfected with PDL241 expression plasmid DNA by electroporation. Transfectants that had stably integrated the expression plasmid were selected in the presence of mycophenolic acid in DMEM medium containing 10% fetal bovine serum. Starting from an NS0-W transfectant that produced a high level of PDL241, subcloning was performed by limited dilution cloning. A subclone with acceptable productivity and product characteristics was chosen and designated 26-5C6.

6.1.5. Enavatuzumab

[0119] Mouse myeloma cell line NS0-W (W indicates that the NS0 cells were weaned from their requirement for serum and cholesterol) as described by Hartman *et al.*, 2007, Biotechnol. Bioeng. 96(2):294-306, was maintained in a protein-free basal medium. NS0-W cells were transfected with pHu19.2.1 expression plasmid DNA by electroporation. Transfectants that had stably integrated the expression plasmid were selected in the presence of mycophenolic acid in DMEM medium containing 10% fetal bovine serum. Starting from an NS0-W transfectant that produced a high level of PDL192,

subcloning was performed by limited dilution. A subclone with acceptable productivity and product characteristics was chosen as the final production cell line and designated 299-9.

6.2. Production of Antibodies

6.2.1. Cell Culture and Recovery

[0120] Cells are thawed from a single cell bank vial and expanded in progressively larger volumes within T-flasks, roller bottles, spinner flasks, and bioreactors until the production scale is achieved. Upon completion of the production culture, the cell culture fluid is clarified by centrifugation and depth filtration, and transferred to a harvest hold tank. The production culture duration is approximately 10 days.

[0121] Cell culture and recovery can be carried out in a variety of different cell culture facilities using standard equipment, as is known in the art. In another example, cells are thawed from a single cell bank vial and expanded in progressively larger volumes within shaker flasks and bioreactors until the production scale is achieved. Upon completion of the production culture, the cell culture fluid is clarified by centrifugation and depth filtration, and transferred to a harvest hold tank. The production culture duration is approximately 10 days.

6.2.1.1. Inoculum Preparation

[0122] Production batches are initiated by thawing a single cell bank vial. To generate control media (*i.e.*, without excess glycine), cells are transferred to a T-flask containing a chemically-defined medium, Protein Free Basal Medium-2 (PFBM-2). Custom Powder for making PFBM-2 can be ordered from Invitrogen by requesting Hybridoma-SFM media powder prepared without NaCl, phenol red, transferrin, and insulin, including a quantity of EDTA iron (III) sodium salt that, when reconstituted, yields a concentration of 5 mg/L, and that has quantities of the remaining components adjusted such that, when reconstituted, their concentrations are the same as reconstituted Hybridoma-SFM. Prepared PFBM-2 medium contains the following components: 8 g/L Custom Powder; 2.45 g/L sodium bicarbonate; 3.15 g/L NaCl; and 16.5 g/L D-glucose monohydrate (15 g/L glucose). The concentration of glycine in the PFBM-2 medium is 2 mM.

[0123] To produce a glycine medium, the PFBM-2 is first produced as described above. Additional glycine (*e.g.*, 5 mM, 15 mM, or 30 mM) is then added to the PFBM-2 medium. To ensure that the high glycine medium has approximately the same osmolality as the PFBM-2 control medium, osmolality is

adjusted by adding an appropriate level of NaCl. For instance, Table 8 shows the amount of NaCl that is added to the control medium and to three high glycine media to achieve an osmolality of approximately 300 mOsm/kg.

Table 8			
Media	NaCl (g/L)	Total Glycine (mM)	Final Osmolality (mOsm/kg)
2L Control	2.8	2	295
2L w/ extra 5mM Gly	2.8	7	298
2L w/ extra 15mM Gly	2.5	17	301
2L w/ extra 30mM Gly	2.1	32	300

Table 8: Concentration of NaCl in control medium and high glycine medium.

[0124] The cells are expanded by serial passage into roller bottles or spinner flasks every two days thereafter. T-flasks, roller bottles, and spinner flasks are placed in an incubator operating under a temperature set point of 37°C under an atmosphere of 7.5% CO₂ for T-flasks and roller bottles and 5% CO₂ for spinner flasks.

[0125] The spinner flasks are supplemented with 5% CO₂ either by overlay into the headspace or by sparge into the culture, depending on the cell culture volume, and impeller speed is controlled at constant revolutions per minute (RPM). The target seeding density at all inoculum expansion passages is approximately 2.5×10^5 viable cells/mL.

[0126] The cells are expanded by serial passage into shaker flasks every two days thereafter. Shaker flasks are placed in an incubator operating under a temperature set point of 37°C under an atmosphere of 7.5% CO₂.

[0127] The shaker flasks are agitated at constant revolutions per minute (RPM) on a shaker platform in the incubators. The target seeding density at all inoculum expansion passages is approximately $2.2 - 2.5 \times 10^5$ viable cells/mL.

[0128] Approximately 14 days following cell bank thaw, when a sufficient number of viable cells have been produced, the first of several, typically three or four, stainless steel stirred-tank seed bioreactors is

inoculated. Prior to use, the seed bioreactors are cleaned-in-place, steamed-in-place, and loaded with the appropriate volume of PFBM-2 culture medium. The pH and dissolved oxygen probes are calibrated prior to the bioreactor being steamed-in-place. The first seed bioreactor is inoculated with a sufficient number of cells to target an initial cell density of $2.0 - 2.5 \times 10^5$ viable cells/mL. Sequential transfer to the larger volume (typically, 100L to 300 L and then to the 1,000 L seed bioreactors, or 60L to 235L, 950L, and 3750L seed bioreactors) is performed following approximately two days of growth in each reactor and target initial cell densities of $2.0 - 2.5 \times 10^5$ viable cells/mL. Culture pH is maintained by addition of either CO₂ gas or 1 M sodium carbonate (Na₂CO₃) via automatic control. The target operating conditions of the seed and production bioreactors include a temperature set point of 37°C, pH 7.0 and 30% dissolved oxygen (as a percentage of air saturation). The 100L, 300L and 1,000L bioreactors are agitated at 100 rpm, 80 rpm and 70 rpm, respectively. In some instances, the target operating conditions of the seed and production bioreactors include a temperature set point of 37°C, a pH of 7.0 with CO₂ sparge and base addition control and 30% dissolved oxygen (as a percentage of air saturation). The larger volume bioreactors can be agitated at speeds of 100 rpm, 80 rpm, 70 rpm, or 40 rpm.

6.2.2. Cell Culture Production Bioreactor

[0129] After approximately 2 days in the 1,000 L seed bioreactor, the inoculum is transferred into a stainless steel stirred-tank production bioreactor. The production bioreactor has a working volume of approximately 10,000 L. Prior to use, the bioreactor is cleaned-in-place, steamed-in-place, and loaded with approximately 4,000 L of PFBM-2 control medium or the high glycine media. The pH and dissolved oxygen probes are calibrated prior to the bioreactor being steamed-in-place.

[0130] In another example, the inoculum is grown in a 3750L seed bioreactor before transfer to a stainless steel stirred-tank production bioreactor with a working volume of approximately 15,000 L, which is cleaned-in-place, steamed-in-place, and loaded with approximately 4,000-7,000 L of PFBM-2 medium or the high glycine media prior to use.

[0131] The target seeding density of the production bioreactor is in the range of $2.0 - 2.5 \times 10^5$ viable cells/mL. A chemically-defined Protein Free Feed Medium concentrate (PFFM-3) (a chemically-defined concentrated feed medium made by reconstituting PFFM3 subcomponents 1 and 2, L-glutamine, D-glucose, sodium phosphate dibasic heptahydrate, L-tyrosine, folic acid, hydrochloric acid, and sodium hydroxide) is added during culture. PFFM3 contains the components shown in Table 9:

Table 9: PFFM3 Medium Components

Component	Concentration
PFFM3 Subcomponent 1 (amino acids)	20.4 g/L prepared
PFFM3 Subcomponent 2 (vitamins and trace elements)	4.93 g/L prepared
L-Glutamine	11.0 g/L prepared
D-Glucose	28.0 g/L prepared
L-Tyrosine, disodium salt	1.32 g/L prepared
Folic Acid	0.083 g/L prepared
Na ₂ HPO ₄ •7H ₂ O	1.74 g/L prepared
Sodium Hydroxide	Varies, pH control
Glacial Hydrochloric Acid	Varies, pH control
WFI water	

[0132] PFFM3 Subcomponent 1 contains the components shown in Table 10 below:

Table 10: PFFM3, Subcomponent 1

Medium Components	MW (g/mole)	Conc. (mg/L)	Conc. (mM)
L-Arginine HCl	211.	1,900	9.00E+00
L-Asparagine Anhydrous	132.1	1,320	9.99E+00
L-Aspartic Acid	133.1	119	8.94E-01
L-Cysteine HCl•H ₂ O	176.0	2,030	1.15E+01
L-Glutamic Acid	147.1	510	3.47E+00
Glycine	75.1	157	2.09E+00
L-Histidine HCl•H ₂ O	210.0	864	4.11E+00
L-Isoleucine	131.2	1,440	1.10E+01
L-Leucine	131.2	3,130	2.39E+01
L-Lysine HCl	183.0	2,160	1.18E+01
L-Methionine	149.2	1,260	8.45E+00
L-Phenylalanine	165.2	918	5.56E+00
L-Proline	115.1	806	7.00E+00

Table 10: PFFM3, Subcomponent 1

Medium Components	MW (g/mole)	Conc. (mg/L)	Conc. (mM)
L-Serine	105.1	709	6.75E+00
L-Threonine	119.1	1,220	1.02E+01
L-Tryptophan	204.2	408	2.00E+00
L-Valine	117.1	1,450	1.24E+01

[0133] PFFM3 Subcomponent 2 contains components shown in Table 11 below:

Table 11: PFFM3, Subcomponent 2

Medium Components	MW g/mole)	Conc. (mg/L)	Conc. (mM)
Vitamin B-12	1,355.0	10.72	7.91E-03
Biotin	244.0	0.156	6.39E-04
Choline Chloride	140.0	140	1.00E+00
I-Inositol	180.0	197	1.09E+00
Niacinamide	122.0	31.5	2.58E-01
Calcium Pantothenate	477.0	103.1	2.16E-01
Pyridoxine Hydrochloride	206.0	0.484	2.35E-03
Thiamine Hydrochloride	337.0	99.8	2.96E-01
Putrescine 2HCl	161.1	6.66	4.13E-02
DL-Lipoic thioctic acid	206.0	4.84	2.35E-02
Sodium Pyruvate	110.0	1,716	1.56E+01
Ethanolamine HCl	97.54	76.1	7.80E-01
β-Mercaptoethanol	78.13	60.9	7.80E-01
Linoleic Acid	280.48	0.655	2.34E-03
Pluronic F-68	8,350.0	780	9.34E-02
Potassium Chloride	74.55	432	5.79E+00
Riboflavin	376.0	3.42	9.09E-03
Magnesium Chloride Anhyd.	95.21	446	4.69E+00
Magnesium Sulfate Anhyd.	120.4	762	6.33E+00
Sodium Selenite	172.9	0.140	8.12E-04

Table 11: PFFM3, Subcomponent 2

Medium Components	MW g/mole)	Conc. (mg/L)	Conc. (mM)
Cupric Sulfate•5H ₂ O	249.7	0.1069	4.28E-04
Ferrous Sulfate•7H ₂ O	278.0	6.51	2.34E-02
Potassium Nitrate	101.1	0.593	5.86E-03
Zinc Sulfate•7H ₂ O	287.5	15.0	5.23E-02
Manganese Sulfate, Monohydrate	169.01	0.00264	1.56E-05
Nickelous Chloride, 6-Hydrate	237.7	0.00186	7.81E-06
Stannous Chloride 2H ₂ O	225.63	0.001130	5.01E-06
Ammonium Molybdate 4H ₂ O	1,235.86	0.00193	1.57E-06
Ammonium meta-Vanadate	116.98	0.00913	7.80E-05
Sodium meta-Silicate 9H ₂ O	284.2	2.22	7.79E-03
EDTA, Iron(III), Sodium Salt	367.05	31.2	8.50E-02

[0134] The timing and amount of addition of PFFM-3 to the culture occurs as shown in Table 12 below:

Table 12: Exemplary DAC HYP Bioreactor Feed Schedule

Day	PFFM-3 Amount (% of initial mass)
0	0
1	0
2	4-4.14
3	7.8-8.08
4	7.8-8.08
5	7.8-8.08
6	11-11.38
7	13-13.46
8	15-15.52
9	15-15.52
10	0

[0135] Culture pH is maintained at approximately pH 7.0, preferably between pH 7.0 and pH 7.1, by automatic control of CO₂ gas and 1 M sodium carbonate (Na₂CO₃) addition. Dissolved oxygen content is allowed to drop to approximately 30% of air saturation. An oxygen/air mixture is sparged into the culture to achieve a constant total gas flow rate and dissolved oxygen is controlled by adjusting the ratio of air to

oxygen gases as needed and by increasing agitation speed after reaching a maximum oxygen to air ratio. In another example, agitation is adjusted to maintain a constant power/volume ratio. A simethicone-based antifoam emulsion is added to the bioreactor on an as needed basis based on foam level. Samples are taken periodically to test for cell density, cell viability, product concentration, glucose and lactate concentrations, dissolved O₂, dissolved CO₂, pH, and osmolality. The bioreactor culture is harvested approximately 10 days post-inoculation. Prior to harvest, the bioreactor contents are sampled as unprocessed bulk.

[0136] It will be understood that the feed conditions and the feeding schedule can be adjusted for the production of each antibody to optimize titer. The osmolality of the culture medium may be adjusted as needed to obtain optimal titer. Additionally, glucose and glutamine levels may be adjusted during the production phase to maintain optimal titers.

6.2.3. Harvest and Cell Removal

[0137] Just prior to harvest, the production bioreactor is first chilled to < 15°C, then adjusted to a pH of 5.0 ± 0.1 using 0.5 M or 1 M or 2 M citric acid, and held for a period of approximately 30 – 90 or 45 – 60 minutes to flocculate the cells and cell debris prior to transfer to the harvest vessel. The pH-adjusted harvest is then clarified by continuous centrifugation operated under predefined parameters for bowl speed and flow rate as defined in batch record documentation.

[0138] The centrate is filtered through a depth filter followed by a 0.22 µm membrane filter and collected in a pre-sterilized tank. The cell-free harvest is adjusted to an approximate pH of 6.4 using a 1-2 M Tris solution and stored at 2–8°C for further processing. In some instances, this pH adjustment occurs within 12 hours of the original bioreactor pH adjustment to pH 5.0.

6.2.4. Antibody Purification

[0139] Harvest materials from pilot scale runs (50 liters and above) were purified based on three chromatography techniques (MabSelect Protein A affinity chromatography, Q-Sepharose anion exchange chromatography, and CM-Sepharose cation exchange chromatography) in combination with a low pH viral inactivation step, a viral filtration step, an ultrafiltration/diafiltration step, and a formulation step. Materials from 2 liter harvest were processed through Protein A column followed by Size-Exclusion chromatography.

6.3. Determination of Glycosylation Profile

6.3.1. Materials and Methods

[0140] Purified antibodies from different culture conditions (control condition with low glycine vs. experimental condition with high glycine) were analytically characterized. Peptide mapping was used to quantify different glycoforms in the antibody products. Antibody was first reduced with dithiothreitol, alkylated with iodoacetic acid, and then digested with trypsin, and finally analyzed by RP-HPLC with MS detection. The peak areas of each glycoform were obtained and the relative percentage of each glycoform was then calculated from the total peak areas.

6.3.2. Results

[0141] The relative percentages of each glycoform present in the five different antibodies produced from NS0 cells cultured in either control basal medium containing 2 mM of glycine or basal medium supplemented with 15 mM (with a total concentration of 17 mM) are displayed in Table 13. The percentage increase of the two non-fucosylated glycoforms for five different antibodies, G0 –GlcNAc-Fucose glycoform and Man5 glycoform, formed in the medium supplemented with glycine relative to the control medium are shown in **FIGURE 2** and **FIGURE 3**. The combined total percentage increase of non-fucosylated antibody relative to the control is shown in **FIGURE 4**. The data indicate that antibodies from cells cultured under high concentration of glycine exhibit higher levels of non-fucosylated glycoforms than the same antibodies from the control process with a low concentration of glycine. With respect to the G0 –GlcNAc-Fucose glycoform, four of the five antibodies from cells cultured in the higher glycine concentration culture medium exhibit 150% to almost 300% of this glycoform relative to the control. With respect to the Man5 glycoform, the range for four of the five antibodies is 150% to >200% increase of this glycoform relative to the control. Looking collectively at the total amount of non-fucosylated antibody, all five of the antibodies exhibit a 1.5 -2.5 times increase when cells are cultured in the higher glycine concentration media.

TABLE 13						
	G0-GlcNAc-Fucose	Man5	Total Non-fucosylated Ab	G0-GlcNAc	G0	G1
Elotuzumab						
1kL control	1.6	2.0	3.6	13.3	68.9	14.2
100L with extra glycine	2.7	4.4	7.1	13.3	70.2	9.4
PDL241						
2L control	4.9	7.4	12.3	20.6	58.0	9.1
2L with extra glycine	6.0	11.8	17.7	20.7	56.6	5.0
PDL192						
1kL control	1.8	2.1	3.9	9.7	76.7	9.7
50L with extra glycine	4.2	4.4	8.6	11.6	75.2	4.5
Daclizumab						
2L control	1.4	1.0	2.4	7.7	72.5	17.4
2L with extra glycine	4	1.9	5.9	14.6	69.3	10.2
M200						
2L control	0.4	0.4	0.8	4.3	66.1	28.8
2L with extra glycine	0.7	0.5	1.2	5.7	80.2	12.9

Table 13: Glycosylation profile of four antibodies produced by methods in accordance with the present disclosure

[0142] In the dose response study, the percentages of each glycoform present in antibody PDL192 (enavatuzumab) produced from cells cultured in either control basal medium containing 2 mM glycine or basal medium supplemented with different concentrations of glycine (7, 17, and 32 mM) are displayed in Table 14. The percentage increase of the two non-fucosylated glycoforms of PDL192, G0 –GlcNAc-Fucose glycoform and Man5 glycoform, formed in the medium supplemented with glycine relative to the control medium are shown in **FIGURE 5**. The data indicate that PDL192 produced under conditions with extra glycine exhibit a higher level of non-fucosylated glycoforms than the antibody produced from the control process. More specifically for the non-fucosylated G0-GlcNAc-fucose glycoform, the amount of the glycoform increases with increased concentration of glycine in the culture medium in a dose-dependent manner. The percentage of increase ranges from 120% to >160% relative to the control as glycine concentration increased from 7 to 32 mM.

TABLE 14							
PDL192	G0-GlcNAc-Fucose	Man5	Total Non-fucosylated Ab	G0-GlcNAc	G0	G1	CD16a Binding relative to Reference
2L control	2.1	5.2	7.3	12.3	70.6	9.8	130
2L with extra 5 mM glycine	2.6	6.3	8.9	15.4	71.3	4.4	146
2L with extra 15 mM glycine	3.3	7.7	11.0	13.5	70.5	4.9	151
2L with extra 30 mM glycine	3.5	6.3	9.8	14.6	71.5	4.0	144

Table 14: Glycosylation profile and CD16a binding of PDL192 produced in culture media with excess glycine

6.4. CD16a Binding Assay

6.4.1. Materials and Methods

[0143] A CD16a binding assay was performed using AlphaScreen (PerkinElmer) method to assess the binding potency of the antibody Fc region of four different antibodies to human CD16a receptor. The antibody solution was first mixed with a recombinant human CD16a solution and assay buffer, and then Alphascreen donor beads and antibody acceptor beads were added. The mixture was incubated in a light protected location for 4 hours at room temperature and the fluorescent signal was detected using a plate reader with laser excitation at 680 nm and light emission 520-620nm. The binding potency relative to the antibody reference cultured in a basal medium without excess glycine was reported.

6.4.2. Results

[0144] The results from the CD16a potency assays for four different IgG1 antibodies (elotuzumab, daclizumab, PDL192 and PDL241) are shown in Table 15. All four IgG1 antibodies from cells cultured under the high concentration of glycine consistently showed more than a 40% increase in binding affinity to the human CD16a receptor, and in the most extreme case exhibited a twofold increase in terms of binding potency relative to the control antibodies produced in basal media without excess glycine (*i.e.*, culture media 2 mM glycine). **FIGURE 6** shows the relative binding potency to the CD16a receptor for the four IgG1 antibodies. The amount is expressed as a percentage relative to the CD16a binding affinities of the same antibodies produced by NS0 cells cultured in control basal medium without additional glycine supplementation.

TABLE 15	
Elotuzumab	CD16a Binding Relative to Reference
1kL control	100%
100L with extra glycine	128%
1kL with extra glycine	146%
PDL241	
2L control	147%
2L with extra glycine	277%
250L control	100%
100L with extra glycine	137%
PDL192	
1kL control (GMP)	65%
1kL control	96%
100L control	110%
50L with extra glycine	136%
Daclizumab	
2L control	69%
2L with extra glycine	137%

Table 15: CD16a Binding of four antibodies produced by methods in accordance with the present disclosure

[0145] The CD16a potency results from dose response study on PDL192 are shown in Table 14 and **FIGURE 7**. PDL192 from cells cultured under conditions supplemented with extra glycine of 5, 15 and 30 mM showed higher CD16a binding affinity than the antibody from the control process, although a dose-dependent increase in CD16a binding was not observed.

6.5. Antibody-Dependent Cellular Cytotoxicity (ADCC)

6.5.1. Materials and Methods

[0146] ADCC activity of the expressed antibody was analyzed *in vitro*. Target cells were first labeled with ⁵¹Cr and effector cells (human peripheral blood mononuclear cells, PBMC) were prepared from whole blood. The cells and antibody solution were then incubated at 37°C for 4 hours. The radioactivity in the supernatants was measured for experimental release (E), spontaneous release (S, release from target without effector cells and antibody), and total lysate (T, release from target cells treated with detergent 1% Triton X-100). The percent cytotoxicity was calculated as [(E-S)/(T-S)]×100.

6.5.2. Results

[0147] The results from the ADCC assays of four different antibodies (elotuzumab, PDL241, PDL192 and daclizumab) are shown in **FIGURES 8A-C, 9A-B, 10A-B and 11A-B**, with each assay performed on PBMCs from two or three different donors. In all four figures, antibodies from cells cultured under the higher concentration of glycine showed increased ADCC activity compared to the same antibodies from cells cultured under the control process. The results indicate that ADCC activity is consistent with CD16a binding potency, and both assay results correlate with the glycosylation patterns of the antibodies.

7. SPECIFIC EMBODIMENTS, INCORPORATION BY REFERENCE

[0148]

[0149] While various specific embodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s).

WHAT IS CLAIMED IS:

1. A method of producing an IgG1 antibody, comprising:
culturing NSO cells engineered to secrete and express the IgG1 antibody in a cell culture medium comprising glycine at a concentration between 5 mM and 30 mM under conditions suitable for expression and secretion of the IgG1 antibody, thereby producing the IgG1 antibody.
2. The method of claim 1, wherein the concentration of glycine is in the range of from 10 mM to 25 mM, or 15 mM to 20 mM, or 16 mM to 18 mM.
3. The method of any one of claims 1-2, wherein the medium is a protein- free medium.
4. The method of any one of claims 1-3, further comprising recovering the IgG1 antibody.
5. The method of claim 4, wherein recovering the IgG1 antibody comprises the step of separating the NSO cells from the culture medium, and optionally purifying the IgG1 antibody.
6. The method of any one of claims 1-5, wherein the NSO cells are seeded to a density of 1.5×10^5 cells/mL to 2.5×10^5 cells/mL, prior to said culturing.
7. The method of any one of claims 1-6, wherein the IgG1 antibody comprises a VH region of the amino acid sequence of SEQ ID NO:1 and a VL region of the amino acid sequence of SEQ ID NO:2, optionally wherein the IgG1 antibody has a full heavy chain amino acid sequence of SEQ ID NO:3 and a full light chain amino acid sequence of SEQ ID NO:4.
8. The method of any one of claims 1-6, wherein the IgG1 antibody comprises a VH region of the amino acid sequence of SEQ ID NO:5 and a VL region of the amino acid sequence of SEQ ID NO:6.
9. The method of claim 8, wherein the IgG1 antibody has a full heavy chain amino acid sequence of SEQ ID NO:7 and a full light chain amino acid sequence of SEQ ID NO:8.
10. The method of any one of claims 1-6, wherein the IgG1 antibody comprises a VH region of the amino acid sequence of SEQ ID NO:9 and a VL region of the amino acid sequence of SEQ ID NO:10.

11. The method of claim 10, wherein the IgG1 antibody has a full heavy chain amino acid sequence of SEQ ID NO:11 and a full light chain amino acid sequence of SEQ ID NO:12.
12. The method of any one of claims 1-6, wherein the IgG1 antibody comprises a VH region of the amino acid sequence of SEQ ID NO:13 and a VL region of the amino acid sequence of SEQ ID NO:14.
13. The method of claim 12, wherein the IgG1 antibody has a full heavy chain amino acid sequence of SEQ ID NO:15 and a full light chain amino acid sequence of SEQ ID NO:16.
14. The method of any one of claims 1-6, wherein the IgG1 antibody comprises a VH region of the amino acid sequence of SEQ ID NO:17 and a VL region of the amino acid sequence of SEQ ID NO:18.
15. The method of claim 14, wherein the IgG1 antibody has a full heavy chain amino acid sequence of SEQ ID NO:19 and a full light chain amino acid sequence of SEQ ID NO:20.

1/8

Typical N-Linked Glycan Structures




FIGURE 1

2/8




FIGURE 2




FIGURE 3

3/8




FIGURE 4




FIGURE 5

4/8




FIGURE 6




FIGURE 7

5/8




FIGURE 8A




FIGURE 8B




FIGURE 8C

6/8




FIGURE 9A




FIGURE 9B

7/8




FIGURE 10A




FIGURE 10B

8/8

Donor #2: ADCC Activity of
Daclizumab measured by ^{51}Cr -release
022409AK1




FIGURE 11A

Donor #1339: ADCC Activity of
Daclizumab measured by ^{51}Cr -release
022409AK2




FIGURE 11B

